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Abstract
This thesis is concerned with investigating the selectivity, mechanisms of action and
optimisation of delivery of the novel anti-cancer agent dll520. D11520 is an attenuated
adenovirus that has been genetically modified to have a selective cytolytic action against
tumour cells deficient in function of the p53 tumour suppresser protein. This action
follows on from a localised, productive infection of the virus. As defects in p53 gene
function are known to occur in at least 60% of human solid malignancies this makes
selective targeting of such cells an ideal strategy for anti-cancer gene therapy. The virus
has been previously tested by direct intra-tumoural injection, in patients with recurrent
SCC of head and neck and advanced tumours of ovary and GI tract and been found to
have anti-tumour activity in a certain number of cases. In clinical trials the side effect
profile of the virus has been generally favourable, with fewer adverse effects than would
be expected with the standard systemic treatments currently available to treat these
advanced tumours.
Recent publications have raised questions about the mechanism of action of the virus,
with particular reference to its p53 selectivity. Some in-vitro experimental series have
cast doubt on the selective action of dl 1520 in p53 null tissues as detailed above. One
research group has reported experimental findings that could be interpreted as suggesting
that p53 is required for the virus to cause cell death, in direct contradiction to the
accepted mode of action of the virus. Despite much evidence from laboratory based
studies, there have not to date been sufficient data from earlier clinical trials to
convincingly support the hypothesis of p53 selectivity. One reason for this is that
samples taken from tumours treated with the virus have been relatively small and this
has led to inadequate biopsy material for detailed histological analyses.
This thesis was conducted to report on experimental and clinical studies to further
elucidate the p53 selective aspects of the action of dl 1520 and how this relates to viral
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spread and mechanism of cell death within tumours treated with the virus. Earlier
experimental work has pointed to the therapeutic potential of dl 1520 when combined
with conventional cytotoxic agents. The study confirms that the virus can act in an
additive fashion with standard chemotherapeutic agents in a tissue culture model. This
effect is dependent on the p53 status of the cell line used when cells are exposed to the
virus for a period sufficient for viral replication to take place. The virus under these
circumstances causes greater cell death in p53 negative cells.
Using a murine xenograft model with cell lines matched for p53 status it is shown that
the virus replicates and spreads preferentially in p53 negative cell lines, although it can
exist and replicate within p53 competent tumours as well. Viral presence is maximal at
72hrs following administration. It is also demonstrated that the use of the local
anaesthetic lignocaine increases the distribution of virus when used as a carrier medium.
This effect is probably due to local vasodilatation. Using hyaluronidase as a carrier
medium also increases viral distribution, an effect that is probably due to the liquefaction
of ground substance in the tissue interstitium causing decreased resistance to the flow of
the virus.
The clinical trial investigated for the first time the effect of a single intra-tumoural
injection of the virus into oral squamous cell carcinoma in patients who have received no
prior therapy. These patients were scheduled for potentially curative surgery 1-14 days
following injection. A concomitant injection into adjacent normal tissue with dl 1520 was
also administered prior to surgical resection of the tumour and biopsy of the injected
normal tissue. Data from this trial show that the virus can exist and replicate within
human squamous cell carcinoma. Significantly more virus is detected in tumour tissue
than normal tissue and we have shown that viral replication is probably at least partially
p53 dependent. Injecting the virus into normal tissue samples causes no evidence of
tissue necrosis, even though virus can be detected within some normal tissue samples.
These studies suggest that the virus is selective for replication in tumour tissue as
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opposed to normal tissue. This selectivity is probably dependent on the p53 status of
these cells. In those cases where virus was detected in normal tissue biopsies there was
immunohistochemical evidence of abnormality in the p53 protein in these samples. It is
postulated that within some of these normal tissue biopsies there were abnormalities of
function of the p53 protein that allowed the survival of the virus.
The mechanism of cell death within the injected samples was also investigated looking
at levels of apoptosis within the specimens. Following the injection of virus into normal
tissue at 24 hours there is a higher than expected level of apoptosis. It is probable that
this apoptosis is caused by the adenovirus causing a p53 modulated cell death as would
be predicted in normal, p53 competent tissue. This suggests the agent will have little
capacity to replicate within normal tissues.
The circulating immune response to adenoviral injection was also investigated. It was
demonstrated that at 24 hrs following injection there was a transient drop in CD4+ve
lymphocytes in the peripheral blood. The mechanism of this drop is not clear at present
nor whether there is any clinical sequelae related to it. No clinical effect on patients due
to this drop was noted.
This thesis represents a body ofwork involving the novel anti-cancer agent dl 1520. The
results indicate that the virus does have a selective propensity for survival and
replication within p53 deficient tumour cells. The virus can exist within normal cells and
p53 competent tumour cells but to a lesser extent than in p53 competent cells. There is
no evidence that the virus can harm normal tissues, even when directly injected into
them. This is an important factor in considering the safety of a novel agent such as
dll520. The results of the above experiments show that the agent can safely be used for
direct intra-tumoural injection for the treatment of squamous carcinoma of the head and







D11520 is an attenuated adenovirus currently under investigation as a novel anti-cancer
agent. The adenovirus has been modified in such a way that it will in theory destroy
tumour tissue by direct cytolysis of tumour cells. This follows a localised productive
infection within these tissues [1]. The virus has been modified so as to have a specific
action against cells lacking function of the p53 tumour suppressor gene with little or no
adverse effect on p53 competent tissues. As many human malignancies are characterised
by mutation of the p53 gene or lack of function of the protein this selective targeting
makes the dll520 virus an attractive possibility as a therapeutic agent[2]. Human intra¬
oral SCC has a particularly strong association with p53 abnormalities [3, 4]. The
specificity for p53 deficient cells is due to the inability of the virus to manufacture the
E1B viral protein, which is necessary to bind and inactivate the p53 tumour suppresser
protein [5]. Modifications to the genome of the virus itself have been made so that it
does not express the E1B 55,000 gene product [6]. The virus contains a deletion between
nucleotides 2496 and 3323 in the ElB region. There is also a C to T transition that
generates a stop codon at codon 2022 so preventing expression of even a truncated
protein [7].
The human adenovirus is a common human pathogen that in the wild type causes mild
upper respiratory tract infections in humans [8]. Normally, adenovirus inoculation into a
cell causes the cell to enter S-phase due to the action of the adenoviral ElA protein. This
effectively switches on the cell cycle to create a suitable environment for viral
replication [9]. Adenoviral infection however also triggers the activation of the tumour
suppressor gene p53 leading to p53-modulated apoptosis via a pathway involving the
retinoblastoma gene and pl4ARF (see below for detailed description) This leads to the
death of the host cell before viral replication can take place. In this way p53 is activated
as part of the cellular protective mechanism against viral infection. The viral El B protein
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of adenovirus can block this p53-mediated effect so inhibiting apoptosis and allowing
cell entry into S-phase, which is permissive for viral replication. D11520 lacks this E1B
function and so is purported to be severely replication deficient in p53 competent cells.
Many human malignancies are characterised by dysfunctional p53 as part of the
fundamental genomic change leading to or propagating malignancy [10] [11] [12]. The
attenuated adenovirus dl 1520 is thought to have selective anti-cancer activity, the
selectivity being due to this lack of functional p53. The mechanism of cell death is
cytolysis of cancer cells. It should cause little or no harm to normal tissues [12, 13]. This
thesis is concerned with a series of experiments and a clinical trial to further investigate
the action of dl 1520 both in terms of laboratory based in-vitro and in-vivo models and
also in a clinical trial involving the administration of the agent to human subjects.
Factors affecting the optimal delivery of the virus have also been investigated.
1.2.1 Gene therapy of malignant disease
Cancer in humans is the third commonest cause of death in the Western world. Standard
treatments include surgery and radiotherapy to treat localised disease, and chemotherapy
[14]. Chemotherapy can be administered systemically to try to destroy metastatic lesions
or to address a recurrent tumour that cannot be surgically removed. Surgery and
radiotherapy can be used with curative intent or for palliation whilst chemotherapy is
most commonly used as an adjuvant to other treatments or as salvage treatment once
other therapies have failed. Surgery and/ or radiotherapy can be very effective first line
therapies especially for early cancers where the disease is localised to one anatomical
area [15]. Once a tumour recurs following such treatment or for disease where there is
spread either to lymph glands or distal metastases these treatments can usually only offer
palliation. Chemotherapy may be indicated to try to deliver a systemic therapy
throughout the body to control disease. Squamous cell carcinoma (SCC) of the head and
neck is such a form of cancer, which has only a limited response to chemotherapy once
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disease is recurrent or metastatic [16].
For most solid tumours attempts to control widespread or recurrent disease are palliative
only and any response is partial and short-lived. If for example a patient has a recurrence
of disease following surgical treatment for squamous tumour of the head and neck they
have a life expectancy of only three months. This is not significantly improved with
chemotherapy although there have been some promising recent trials [17, 18].
Most chemotherapy agents act to selectively kill cancer cells due to specific genetic
differences that these cells possess as compared to normal cells. One example is the
commonly used DNA damaging agent cisplatin that relies on the function of the p53
tumour suppressor gene to cause apoptosis in cancer cells following exposure to the
drug. Cancer cells that are resistant to cisplatin often have reduced function of the p53
protein [19]. The action of cisplatin therefore relies on the function of cell cycle
regulatory proteins such as p53, which are required to couple the activity ofDNA
damaging agents to the cell death apoptotic pathway [20]. Another example is the anti-
tumour agent Camptothecin that targets DNA Topoisomerase I. This allows a selective
toxicity against tumour cells that have a high turnover but the therapeutic index is often
narrow. This is because all cells with a relatively high turnover are targeted along with
cancer cells leading to side effects such as hair loss, immunosupression and gastro¬
intestinal upset. The combination of limited clinical effect and poor side effect profile of
chemotherapy for most recurrent or metastatic cancer mean that alternative treatments
for such disease are required that would have greater specificity for tumour cells both
locally recurrent and metastatic.
One group of treatments that can potentially address these problems is gene therapy.
Gene therapy can be defined as follows: 'Somatic gene therapy research is considered to
include the use of genetically modified organisms and/ or modified nucleic acids or
modified human somatic cells for potential research or for other research purposes in
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human subjects.'
Gene therapy for cancer entails trying to correct the genetic fault within cancer cells at
the molecular level either leading to the death of these cells or transforming the cells out
of their cancerous state [21]. Common genetic problems in cancer cells include lesions
of dominant oncogenes or tumour suppressor genes [22]. Gene therapy for cancer aims
to alter these genetic faults. This can either lead to destruction of tumour cells or
transformation of a malignant cell back to a normal phenotype. It is hoped that this might
lead to improved therapies for cancer. There are several potential strategies by which this
can be achieved [23]:
1.2.2 1- Strategies for gene therapy
1. A functional gene can be inserted to override the effect of a dysfunctional gene e.g. a
tumour suppressor gene. The p53 gene for example is mutated in many human cancers
and this loss of p53 function is thought to be a fundamental change leading to malignant
change. By inserting a functional copy of the p53 gene into cancer cells this could lead to
the cell transforming to a non-malignant type [24-26].
2. Homologous recombination is the technique whereby exogenous DNA is integrated
into a host cell genome [27]. This allows for subtle modifications of point mutations or
insertions with the potential for specific gene repair [28, 29]. It is possible that by
identifying specific target genes involved in carcinogenesis and replacing these with the
functionally normal DNA segment homologous recombination could be used as a
therapeutic strategy [30].
3. A suicide gene can be added selectively to tumour cells that codes for an enzyme
which converts a harmless pro-drug into a cytotoxic agent. This would lead to a local
accumulation of the cytotoxic agent only in the cancer cells targeted by the gene therapy
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agent [31]. Using this technique there is also the bystander effect whereby cells not
directly targeted with a gene therapy agent are nevertheless killed due to local cytotoxic
activity [32, 33]. Bystander effect can also be seen in strategies that rely on the host
immune system to destroy tumour cells. For example tumour cells can be genetically
modified with the herpes simplex virus and then targeted with Gancyclovir. This suicide
gene therapy has been shown in mice to induce an immunologically mediated bystander
effect, which can be maximised by prior immunisation of the mice against tumour cells
[34] [35]
4. Anti-sense gene therapy involves the transcription of a mRNA product that is
transcribed in the opposite direction of a target oncogene. This mRNA segment would be
able to bind to the target oncogene effectively blocking the production of the oncogenic
protein [36]
5. Certain small inhibitory RNA molecules are known to suppress the expression of
specific proteins [37]. These have been used experimentally to reduce the expression of
certain key proteins important in DNA double strand break repair, potentially rendering
target tumours more radio and chemo-sensitive [38].
6. Anti angiogenic therapies target the blood supply of tumours using anti-angiogenic
factors. In a mouse model it has been shown that intra-peritoneal delivery of anti-
angiogenic factors can inhibit breast tumour formation [39].
7. Protective gene therapy involves the potential use of gene therapy to insert genes
coding for protective proteins which could allow for higher than normal doses of
cytotoxic drugs to be administered. One such example is the Multi Drug Resistance
protein which is known to protect normal tissues from certain anti-cancer drugs [40].
8. Immunotherapy strategies can be used which are particularly suited to treat
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disseminated disease, due to the systemic nature of the immune system. Strategies can
involve activating an antibody or cell mediated immune response against specific tumour
antigens [41]. Current research strategies in this field include immunisation with tumour
cell vaccines; immunisation with tumour peptides or DNA encoding tumour peptides
[42]. It is also possible to attempt to enhance immunity by blocking inhibitory factors
acting on T-cells.
Before gene therapy can be effective several steps must be taken. The target gene must
be identified and the desired DNA produced. The genetic material must then be inserted
in to the desired cells either within the host directly (in-vivo) or following manipulation
of the target cells outwith the host (ex-vivo). Vectors for delivering gene therapy are
crucial to the success of these strategies.
1.2.2,2 Vectors in gene therapy
Many different strategies to devise suitable gene therapy vectors have been attempted
[23, 43]: Viral vectors are by far the most efficient and widely used techniques for gene
transfer involve the use of viral vectors. Many attempts have been made to utilise the
ability of viruses to integrate into human cells in the gene therapy treatment of cancer
[44]. The most commonly used viruses include retroviruses and adenoviruses.
Retroviruses integrate their DNA into the target cells thus ensuring any progeny cells
maintain the genetic manipulation. Adenoviruses are capable of carrying large amounts
of genetic information and can enter human cells readily [45, 46].
Non-viral vector techniques can also be used for gene therapy. Naked DNA can be
directly inserted, a process which can be facilitated using electroporation; gene gun;
ultrasound and hydrodynamic pressure [47]. It is also possible to construct vectors
consisting entirely of chromosomal material which can integrate into the genome [48].
These areas can Potentially act as independent domains within the genome. All these
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non-viral vectors have potential advantages in terms of safety and likelihood of eliciting
an immune response, but suffer from relatively low transfection efficiency [49].
1.2.2.3 - Targeting diseased cells
For a gene therapy strategy to be successful in cancer, it is necessary to target cancer
cells involved in the disease process preferentially whilst minimising damage to healthy
tissues. Malignant cells can be ofmany different types and can exist in all areas of the
body. Effective targeting of these cells is therefore desirable to maximise the therapeutic
process and minimise the risk of germ line transduction. This is clearly more important
for systemic gene therapy strategies as opposed to direct intra-tumoural delivery. There
are many potential strategies for targeting under investigation [50].
1.2.2.3.1 - Targeting Gene Delivery
It is possible to target delivery of a gene therapy vector to a specific area. An ideal vector
for gene delivery should be targeted, protected from degradation and safe for systemic
delivery. It should allow for systemmic administration and then go on to accumulate in
the target tissue. Factors such as binding specificity; size of particle; charge of particle
and route of administration will all affect the bio-distribution of a given vector [51].
1.2.2.3.2 - Non-replicative viral vectors
1. Conjugate based targeting allows viral vectors to be targeted by the use of bifunctional
bridging agents which can attach to both the virus in question and a given target tumour
cell type. For example bifunctional crosslinkers that recognise fibroblast growth factor
and epidermal growth factor receptors (both over expressed in many tumour types) have
been developed [52].
20
2. Genetic targeting describes a process whereby a vector virus is modified to bind
preferentially to a selective target cell. This has been demonstrated where ecotropic
murine leukemia virus was modified by the addition of a ligand to bind to EGFR [53]. It
is also possible to restrict the ability of a virus to bind to its natural receptor and
therefore re-direct it to a chosen target cell [54].
1.2.2.3.3 - Replicative viral vectors
Replication competent virus strategies can potentially allow for much greater release of
gene product at a target tissue. The risk of damage to surrounding tissue is however also
potentially less controlled than in replication deficient strategies. Targeting of these
agents is therefore important.
1. Partial de-activation of virus can allow for a virus to selectively replicate only within
target tissues, dl 1520 adenovirus is an example of this strategy and is selective against
p53 deficient tissues due to an ElB gene deletion. This strategy is described in greater
detail below.
2) Control of transcription ofviral genes required for replication can be utilised by
replacing the native viral promotors with other promotors activated by conditions
specific to the target tumour cells. An adenovirus has been thus modified to be activated
in the presence ofhypoxia and oestrogen as a strategy to target breast cancer [55].
3) It is possible to modify the signaling pathway in tumour cells to restrict replication to
certain tissue types. One example is the modification of the adenovirus that has been
modified to replicate selectively in cells with PSA (prostate specific antigen), a protein
strongly associated with prostate cancer [56].
21
1.2.2.3.4 - Non-viral vectors
Non-viral vectors are attractive targets for gene therapy as they are less immunogenic,
have less risk of side effects and are easy to administer. Ligands to specific receptors can
be used to target these agents to specific tumour cell types [57]. One example of this
strategy is the addition of an epidermal growth factor targeted polyethylenime system
that might be used to target breast or prostate cancer where these receptors are over
expressed.
1.2.2.3.5 - Targeted bacterial vehicles
Bacteria are attractive as vehicles for gene therapy due to their large genome and the
potential to control their replication with anti-biotics. Several bacteria are under
investigation as they can be targeted to the relatively anaerobic conditions found in the
centre of tumours. The anaerobic Clostridium sporogens, transfected with cytosine
deaminase, has been used as a suicide gene strategy combined with the pro-drug 5-
fluorocytosine [58]
1.2.2.3.6 - Targeted gene transcription
Targeting gene transcription to specific cells rather that delivery is another strategy
currently under investigation. This is potentially more selective than gene delivery
targeting as most receptor targets are not totally specific to tumour cell types.
1.Tissue specific transcriptional regulatory sequences can be utilised such as the glial
fibrillary acidic protein promoter in glioma cells[50],
2. Promotors specifically activated by conditions prevalent in tumours can be utilised.
One example is hypoxia related gene expression causing hypoxia related gene expression
[59].
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3. Anti-sense oligonucleotides can be used to specifically target mRNA ofpathogenic
genes. In theory this allows for very precise targeting of pathogenic genes, but this
strategy is at an early stage of development [60]
4. DNAzymes are single stranded oligodeo-xylnucleotides capable of cleaving mRNA.
These can be used to specifically target pathological gene products. As an example, the
vascular endothelial growth factor receptor is an important target for anti-angiogenic
gene therapy. This can be targeted by a specific DNAzyme which has been shown to
digest mRNA substrates of this receptor, leading to reduced tumour growth in a murine
model [61].
1.2.2.3.7 - Cells used as carriers
It is possible to utilise various cell types to transport gene therapy agents following
systemic delivery. Clearly these cells need to localise to target tumours. [62].
1. Macrophages can be used to transport transcriptionally targeted vectors to increase
anti-tumour activity [63].
2. T cells can be utilised as carries due to their propensity to extravasate in response to
specific signals. This strategy has been used in T-cells expressing a chimeric T-cell
receptor against CEA, expressed in colorectal tumours [64].
3. Tumour cells, either autologous or allogenic, can in theory be used as vector carriers
as it has been noted that tumour cells bind preferentially to other tumour cells of the
same type [65].
4. Stem cells also have potential as carriers of gene therapy vectors base don the fact that
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these cells can differentiate into different cell lines. This would remove the need for
harvest of the various cell types described above, as they could be grown direct from
stem cells. For example it has been shown that stem cells from bone marrow can
differentiate into endothelial cells [66].
1.2.2.4 - In-vivo and ex-vivo techniques
Gene therapy can be further divided into in vivo or ex vivo techniques. In vivo gene
therapy involves genetically modifying cells within the body by introducing a therapeutic
gene (DNA or viral vectors) via direct administration into the patient through direct
tumoural, intra-venous, intra-peritoneal, intra-muscular or intra-arterial injections. Ex
vivo gene therapy involves genetically modifying cells that have been removed from the
body and culturing them to allow for expansion. This strategy lends itself to techniques
involving cells of the hematopoietic system [67] [68]. The cells are then later
reintroduced to the host. Both methods seek to genetically modify cells in a manner that
will allow for prolonged gene expression.
1.2.3 Clinical trials in gene therapy
The first clinical trial showing proof of principle of gene therapy for malignant disease
was reported in 1996 when Roth et al successfully integrated functional p53 DNA via an
adenoviral vector into recurrent non-small cell lung cancers by direct intra-tumoural
injection [69]. Subsequently evidence of vector-p53 sequences was demonstrated within
the tumour along with evidence of increased apoptosis. The same group have conducted
phase I and II trials using direct intra-tumoural injection of Ad-53, combined with both
chemotherapy and radiotherapy. As with many clinical trials, problems with delivery of
the virus have limited the success of this approach [70]. Prostate cancer has also been
targeted with gene therapy. A phase I trial using intra-prostatically administered
interleukin 2 encased in a DNA-lipid complex in patients with advanced prostate cancer
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showed an increased T-cell infiltration in prostate tissue and a decrease in expression of
prostate specific antigen [71].
Despite this early success and numerous clinical trials there remain many problems with
gene therapy as a treatment for cancer. Difficulties have so far been encountered with
delivery systems, as targeting tumour cells selectively is problematic. To successfully
deal with systemic disease the ideal delivery vehicle would allow repeated systemic
treatments with a selective uptake of the desired gene into tumour cells. Non-viral
delivery systems are relatively inefficient at delivering genetic material and viral vectors
tend to promote a vigorous immune response leading to rapid clearance of a proposed
vector if it is delivered more than once [46, 72]. Direct intra-tumoural injection is
possible and may elicit less of an immune response but will not deal with inaccessible,
blood borne or microscopic disease.
There are safety issues concerning the administration of gene therapy, particularly
associated with viral vectors. Toxic viraemia; the effect of virus on the liver or other
organs; passage of virus around the community and local tissue reactions are all possible
complications with these approaches.
1.3.1 Viral gene therapy using targeted cvtolvsis
Another possible use of the technology of gene therapy is to utilise the direct cytotoxic
effect of a virus targeted to tumour cells. Many viruses can infect cells and after a period
of replication lyse these cells to release further virus particles which can go on to infect
surrounding cells leading to a productive viral infection [73]. It has been known for
almost a century that certain viral infections or rabies vaccination could occasionally
lead to remission in malignant disease. Many researchers have thought of using oncolytic
viruses in patients with advanced cancer and the first successful use of an adenovirus
was reported in 1956 when patients with advanced cervical cancer were treated with
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direct intra-tumoural injection with some favourable responses [74].
Modern techniques allow for high levels of viral titre to be manufactured and there has
been a recent upsurge in interest in this form of therapy. The idea of a virus targeting
tumour cells directly is attractive for many reasons. It is known that after a small number
of tumour cells are killed by viral replication and cytolysis in this way there is a
significant bystander effect [6]. If a virus is directly lytic to tumour cells there is no need
to instil foreign genetic material into human cells. If a virus can somehow be made to
target tumour cells only it should be possible to deliver a highly selective anti-tumour
agent which might be delivered systemically to treat disseminated or microscopic
disease. The side effect profile of such a treatment should be acceptable when compared
to other standard treatment regimes.
An ideal candidate for such a virus would be able to replicate within cancer cells; should
cause only mild symptoms in the host and be non-integrating into human DNA [75],
Adeno-viruses are common human pathogens that fulfil the above criteria. They are
currently favoured for many gene therapy trials as a vector as they can store a lot ofDNA
and integrate into a wide range of host cells [45]. They can also act in a directly cytolytic
fashion following cellular inoculation. The adenovirus is a common pathogen that leads
to upper airway infection and symptoms of coryza or common cold (Fig 1-1). The wild-
type virus typically inoculates into cells and after a period of replication goes on to lyse
the infected cell releasing further virus particles which can go on to infect further cells.
One problem with using adenovirus as a vector is that a large proportion of the
population have been exposed to the pathogen and will have mounted an immune
response, meaning the body will react vigorously to a repeated viral infection [76].
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Figure 1.1- adenovirus structure (University of Leicester Department of
Microbiology and immunoioqy website www-micro.msb.le.ac.uk/)
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The penton fibres consist of a slender shaft with a globular head. They are involved
the process of attachment of the virus particle to the host cell.
1.3.2 Mechanism of cell lysis
The virus initially binds to specific cell surface receptors before being internalised by
endocytosis [8, 73, 77, 78]. Following adenoviral infection of cells a series ofmetabolic
defects appears within the cell notably reduction in RNA, DNA and protein synthesis
coupled with a loss of structural integrity of the cytoskeleton of the cell leading to lytic
cell death. A major effect of this loss ofhost cell protein synthesis is to directly weaken
the cytoskeleton so as to increase cell lysis with subsequent viral spread rather than
simply to direct metabolic activity toward viral product synthesis [79]. This effect takes
approximately 36 hours [80]. Thus if cytolysis is reduced there is a dramatic reduction of
the ability of the adenovirus particles to spread.
1.3.3 d!1520
To be effective as a viral therapy treatment a virus would need to be selective for either
infection of or replication within tumour cells. This would mean that that normal healthy
tissue would not be affected along with any tumour cells. Such selectivity can be
accomplished by making cell entry selective; by making transcription of certain genes
only possible in tumour cells or by removing genetic material necessary for replication in
normal cells but which are not required for replication in tumour cells. There are several
examples of this last type of therapy under investigation. A replication conditional
herpes simplex virus has been used in the treatment of brain tumours [81]. An
adenovirus selective for replication in cells carrying the alpha-fetoprotein promoter has
been used to target hepatocellular carcinoma in nude mice [82]. The dl 1520 adenovirus
falls into this group of treatment strategies.
The attenuated adenovirus dl 1520 was initially developed as a research tool to
investigate the requirements of various viral proteins for transformation of rodent cells
[5]. It is postulated that this virus should be selective for replication in cells deficient in
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the tumour suppressor p53 protein and that this selectivity could lead the virus to be used
as an anti-cancer agent [6]. D11520 has been constructed based on the wild-type type 5
human adenovirus, the wild type version ofwhich is known to cause only mild, self
limiting illness consisting of fever, headache and nausea. The side effect profile of any
modified virus based on an adenovirus would be expected to be favourable as the wild-
type virus only causes mild symptoms under normal circumstances.
1.3.4 Mechanism of action of dl1520
The dl 1520 adenovirus is a gene deleted group 5 adenovirus deficient in the viral E1B
protein. It has also been found that the virus is partially deficient in the expression of
ElA mRNA and protein. It is known that viral replication activates host cell p53 via the
ElA viral early protein. This involves a signalling pathway involving both the
retinoblastoma protein and the tumour suppressor pi 9 ARF. [9]. ElA binds to a product
of the retinoblastoma gene. The retinoblastoma susceptibility gene product, pRb, can
interact with the E2F meaning in effect a loss of Rb gene function. This in turn leads to
the induction ofp53, via an increase in the expression of pl4ARF, which prevents MDM2
controlled degradation of p53 [83] [84]. It is thought that the E1B protein acts to de¬
activate p53 by forming a complex with p53, involving the E40RF6 viral protein [85].
The virus has been constructed to contain an 827-base pair deletion in the ElB region
and a point mutation at codon 2022. This prevents expression of both normal and
truncated forms of the El B protein. This E1B protein, along with E40rf6 protein, can
normally form a complex with the human tumour suppressor p53 protein, leading to p53
inactivation. It appears that this inactivation happens through two distinct mechanisms:
1 .The E1B protein is thought to bind to an area of the p53 protein in the N-terminus at
amino acid residues 22 and 23. This area is known to be important for translational
upregulation of the protein and is also where the MDM protein binds to p53 to cause
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suppression of activity of the protein [12, 86]. Transcriptional upregulation is one of the
processes by which the production of a specific protein can be increased. This is
achieved by a DNA control element frequently found 5' to the start site of a gene. This
element binds to a specific transcription factor that enhances expression of the gene[87].
It seems therefore that the ElB protein bind to specific amino acids within the N-
terminal domain which are important for the positive regulation of transcription of the
protein (see figure 1.2).
Figure 1.2 - regulation of transcription (from Human Genetics, Chapter 2
pg 22. Gardner A. (Pub Arnold))
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Despite being several kb away, an enhancer can switch on a gene by
completing the transcription apparatus and activating the promoter
2. The E1B-55K protein possesses an intrinsic domain that represses transcriptional
activity. This area targets p53 specific promotors via a direct action on p53 that is bound
to DNA [88],
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This inactivation ofp53 is necessary for viral replication following adenoviral infection.
Following viral infection the ElA early viral product normally induces the host cell to
enter the S-phase of the cell cycle to encourage proliferation of cells [89]. This in turn
activates the p53 tumour suppressor gene and it is thought that the pathway of this
activation involves the retinoblastoma protein and the tumour suppresser protein pl9ARF
[9]. This normally leads to controlled cell death by apoptosis so preventing viral
replication and containing any viral infection. E1B viral protein inactivates p53 via the
binding detailed above, allowing viral replication and eventual cytolysis rather that
apoptosis which would curtail intra-cellular viral replication and subsequent spread.
It was originally hypothesised by Dr Frank McCormick that a virus deficient in function
or expression of the E1B protein would have restricted capacity to replicate in normal
cells but in p53 deficient cancer cells it would be replication competent [5]. If dl 1520
infects a cell with a functional p53 the virus cannot block the action of p53 and so the
cell would apoptose, containing any infection and preventing viral replication. In the
case of a cell deficient in p53 function this would not occur and the dll520 virus could
replicate prior to causing cell death by cytolysis and causing a localised productive
infection (see figure 1.3). As p53 mutation and dysfunction is present in at least 60% of
human solid malignancy, including SCC of the head and neck, dl 1520 is able to
selectively infect and destroy many tumour cell lines [90, 91]. The virus should not
cause significant harm to healthy tissue with a functional p53. A significant body of
work has been undertaken both in vivo and in vitro to determine if the dl 1520 virus can
indeed function to cause p53 specific cytolysis in this manner.
Targeted cytolysis via replication competent viruses has many potential attractions as a
highly targeted, potentially systemic treatment with the potential to deal with micro-
metastatic disease. The capacity of the virus to replicate means that effective
amplification of the input dose can take place [92]. There are potential disadvantages
however to this approach. Viruses can trigger inflammatory and immune responses
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which can be unpredictable [93]. Experimental data utilizing these agents has been
derived from studies involving nude mice, where the host immune system plays no part
in fighting a viral infection. All viruses are potentially harmful, even though the
commonly used adenovirus has few significant symptoms in healthy individuals.
Candidates for gene therapy are often immunosuppressed and may succumb to a viral
infection triggered by a gene therapy vector, as evidenced by a subject who died in a
clinical trial utilising adenoviral gene therapy to treat ornithine transcarbamylase (OTC)
deficiency react more strongly to viral infection [94]. Attenuated adenovirae such as
dl 1520 have also lost other functions apart from that allowing for targeting of tumour
cells. D11520 is known to be missing vital E1B functions related to mRNA transport and
so will be attenuated in virulence even in p53 null cell lines [95].
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Figure 1.3 - Mechanism of Action of d!1520.
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The p53 protein is a transcription factor now widely recognised as being ofparamount
importance in the development ofmany examples of human carcinogenesis. Lane et al
identified the protein in 1983 and since this time it has become clear that it has an
important tumour protector role [96]. Mutations or lack of function of p53 are known to
contribute to the formation ofmany if not most solid malignancies in man [13]. This is
particularly so in the case of intra-oral SCC in humans [90, 97].
When functioning normally p53 acts as a guardian of the genomic integrity of the cell. In
healthy cells the protein is expressed but has a very short half-life and is undetectable by
conventional immunohistochemical means. If the cell sustains an insult such as radiation
damage that could lead to DNA damage p53 is activated. The main trigger to this
activation is a double strand break in the DNA. Viral infection also acts to trigger
activation of p53 via the viral E1A gene product [9]. P53 binds to promoter sites of
various genes notably p21 WAF1, gadd45, mdm2, bax, thrombospondin 1 and cyclin-G
all of which are involved in control of the cell cycle [11, 12]. Since its discovery there
has been extensive research on the function of p53. It is known to have a significant role
in controlling the cell cycle and to function as a protective element against carcinogenic
cell damage. Conversely any loss of p53 function is thought to lead to cancer formation
in many instances. For example in squamous carcinoma of the head and neck mutation
of the p53 gene has long been known to be a key feature ofmost of these tumours [98].
This is particularly so in patients with a known history of tobacco and alcohol exposure,
the main risk factors for the disease in the West [91]. It is also known that if the cells
surrounding an excised tumour have p53 mutations the cancer is more likely to recur
than if the resection margins are clear of p53 abnormalities [90]
The protein normally exists as a 53kDalton protein of 393 amino acids, which can be
divided into four structurally separate domains. Following translation the activity of p53
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is thought to be controlled largely by phosphorylation of several well-defined sites
within the N- and C- termini of the protein [99]. Mutant or dysfunctional p53 is a
common finding in more than 50% of human cancers. Several thousand distinct
mutations have been recorded and are catalogued in several data bases available on the
internet (for example the International Agency for Research on Cancer www.iarc.fr/p53/).
The mutation is commonly a missense mutation that leads to the production of an
abnormal protein. This protein then collects in affected cells leading to increased
detection of p53 by immunohistochemical analysis but reduced p53 function [12].
Reduced or absent function of p53 seems to be implicated in a loss of the cells capacity
to protect itself from many outside effects which if unchecked can lead to or encourage
carcinogenesis. Dysfunctional p53 has been found in 60% solid human cancers and
seems to be more common in tumours demonstrating chemo or radio resistance [100,
101].
Normally the p53 protein functions to protect the cell from damage and to prevent any
error within the cell being propagated to future generations [13], P53 can act to regulate
the expression of proteins involved in negative regulation of cell cycle control and can
also reduce transcription of genes responsible for up regulation of cell turnover [102].
There are several mechanisms by which this is thought to happen.
P53 can cause a cell cycle arrest at G1 or can lead to a cell undergoing apoptosis. These
effects act to protect the cell from undergoing cell division under adverse circumstances
so that potentially carcinogenic effects are not propagated. In certain circumstances p53
will trigger a cell to apoptose so as to prevent a harmful effect continuing. p53 is also
activated in response to viral infection in an attempt to prevent intra-cellular viral
replication. This effect is triggered by the early adenoviral product ElA but inhibited by
the adenovirus ElB55Kd protein in the wild-type virus [89].
The half-life of normal p53 is less than 20 minutes and normally the protein exists at a
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low concentration. There is also evidence that p53 can exist in a latent form prior to
activation [11]. Several agents are known to stimulate p53 to cause either cell cycle
arrest or apoptosis. Any DNA damage in a cell signalled by a single strand break or a
increase in levels ofDNA repair elements leads to an increase in p53 levels and an
increase in the half life of the protein [2]. Different types and intensity of radiation
damage can lead to varying levels of p53 expression. Hypoxia or a deficiency of
ribonucleoside triphosphate can all lead to p53 activation as a means ofhalting cell
division under unfavourable conditions [103].
Following activation and transcription p53 can act to prevent cell duplication in several
ways. One down stream gene is p21 [104, 105] and once activated binds to several cell
cycle kinase inhibitors, which can act to prevent the activity ofDNA polymerase.
Experiments with mice which are deficient in p21 have shown a deficient capacity to
produce a G1 arrest in response to DNA damage which suggests that p21 has a role in
this p53 mediated effect [106]. There is also evidence of a p53 dependent G2 arrest
[107] where by p53 can prevent a cell prematurely entering S phase.
P53 is therefore a protein that has been found to be of fundamental importance in human
malignant disease and carcinogenesis. The protein normally exists in low quantities or in
an inactive state but in response to genetic damage or cellular inoculation by a virus the
p53 can respond:
1. To act directly as an anti-mutator
2. To cause cell cycle arrest
3. To cause cell death by apoptosis
If there is a mutation in the p53 gene and these various protective pathways are disabled
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any carcinogenic insult can be propagated potentially leading to tumerogenesis and
cancer formation. The importance of p53 in clinical terms is heightened by the fact that
many anti-cancer agents work via p53 dependent means so that p53 deficient tumour
cells are often resistant to chemotherapeutic agents as well as radiotherapy [108].
1.5 P21 (WAF1)
Two research teams discovered the p21 protein simultaneously. Following on from the
realisation of the importance of p53 in controlling the cell cycle it was found that the
induction of a gene WAF1 was associated with wild type but not mutant p53 expression.
cDNA from this site was also found to suppress many tumour cell lines [104, 109], The
protein product of this gene, p21, was found to tightly bind and inactivate cyclin
dependent kinases (Cdk's) [110]. Cdk's are known to regulate the cell cycle via
phosphorylation of the retinoblastoma gene (Rb) and thus p21 can act as a regulator of
the cell cycle. P21/ WAF1 is induced by p53 and has been shown to accumulate and be
functional in cells undergoing p53 mediated G1 arrest and apoptosis but not in cells
undergoing p53 independent G1 arrest and apoptosis. P21 activation leads to a decrease
in Cdk activity and is a key effector of p53 related G1 arrest and apoptosis and it has
been shown that this function is required for p53 mediated G1 arrest [111]. P21 can also
act as a direct repressor of tumour cell growth and tumourigenicity [112].
1.6 Apoptosis
Apoptosis refers to the pathway of programmed cell death that allows cells to be
destroyed in a controlled manner [113]. The process involves a characteristic pattern of
cytoplasmic changes, chromatin condensation and DNA fragmentation described by
Wylie in 1980 [114]. This capacity of a cell to 'self-destruct' involves the complex
integration ofmultiple control mechanisms [115, 116]. Apoptosis is involved in normal
development of organs. It is also of fundamental importance as a protective mechanism
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against cancer and viral infections and it is this that is of importance in the field of viral
therapy. Various pathways can lead to the triggering of apoptosis but the common final
pathway involves the influx of calcium ions and the activation of an endogenous
endonuclease. This enzyme causes the break up of the nucleus with a characteristic
pattern of nuclear degeneration into apoptotic bodies [117] (see figure 1.4).
In human squamous carcinoma of the head and neck it is thought that the HSP70 protein
can act to prevent apoptosis thereby encouraging cell proliferation [118]. As has been
stated above the adenoviral E1B protein is known to be a potent inhibitor of apoptosis,
an action which is thought to be due to the protein blocking the action of the cell death
promoting Bax protein [119]. Apoptosis can be thought of as a cell's last line of defence
against a carcinogenic insult as the process allows the cell to die in a controlled manner
as a response to carcinogenic insult. Factors that act to block apoptosis take away this
final possibility to prevent propagation of any such carcinogenic effect. Loss of a cells
ability to undergo apoptosis is known to be important in SCC of the head and neck
[120],
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Figure 1.4 - Mechanism of apoptosis (from Edinburgh University,
Department of Pathology www.portfolio.mvm.ed.ac.uk/)
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1.7 Control of the cell cycle
Before a cell can undergo mitosis to create two daughter cells many steps have to be
achieved which are necessarily under tight control. p53 acts as a key regulator of this
turnover as described above. It is known that cyclin dependent kinases (cdk) act to drive
this cell cycle and they in turn are under the control of various G1 cyclins [121]. The
retinoblastoma tumour suppressor gene is one of the key regulators of the cell cycle
through its gene product pRB [122]. Before a cell enters the S-phase of the cell cycle to
allow mitosis, the retinoblastoma gene can be activated by phosphorylation. This can be















growth factors act throughout the G1 gap phase to drive the cell to enter the DNA
synthesis S-phase, eventually leading to mitosis, M-phase. Many regulatory mechanisms
can act to prevent this cell cycle under adverse conditions [124]. Defects in the
regulation of proteins involved in regulation of the cell cycle are implicated in many
human malignancies, and this is known to be important in SCC of the head and neck
[125].
1.8 Controversies involving the mechanism of action of d!1520
This synopsis of the action of dll502 as a p53 specific anti-cancer agent has recently
been called into question. A paper by Hall et al gave results from tissue culture
experiments involving both wild type adenovirus and dl 1520 [126]. Using a cytopathic
effect assay on cell lines with either normal, mutant or absent p53 they assayed the
replication of each virus. They showed that tumour cell lines expressing both functional
and mutant p53 allowed replication of the dl 1520 virus but that replication was greatest
in cells with functional p53. Results using the supernatant of fluid from these
experiments showed that the lack of cytopathic effect in p53 mutant and null cell lines
was not due to lack of replicating virus. They suggest that wild-type p53 may in fact be
required for cell death following adenoviral infection. Further experiments showed that
cell death associated with wild-type p53 was not primarily due to apoptosis, implying
that p53 is a necessary mediator of the cytopathic effect ofwt adenovirus and dll 520.
They conclude that adenovirus of both wt and E1B deficient can replicate within cells of
varying p53 status, but functional p53 may be required for a productive, cytopathic
adenoviral infection.
This is an entirely different interpretation of the action of the virus than had been
suggested previously and is in direct contrast to previous findings that demonstrated that
cells with a mutant p53 were more sensitive to the effect ofdll 520. One weakness of the
paper by Hall et al is that matched cell lines were not used and results were taken after a
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relatively short incubation with the virus. Cells, which were equal in all things except
their p53 status, were not therefore compared. The time-point used for analysis was
relatively early (48hrs) which may not have allowed for the differential effect of viral
replication (maximal at 72 hrs) to take full effect [79]. The authors also acknowledge
that their data on the mechanism of cell death, indicating a lack of apoptosis, was
premature and incomplete. Even allowing for these criticisms, it is clear that further
clarification of p53 requirements for cell death following dl 1520 infection is required.
Other workers have also shown that the virus can replicate within some tumour cells of
wild-type p53 status although in some cell lines there did seem to be a correlation with
p53 status [127]. These workers further demonstrated that the virus could infect and
replicate within some primary human cell lines including keratinocytes and fibroblasts.
The levels of replication were relatively small and only noted at high multiplicities of
infection (MOI). Again these results call into question many of the original assumptions
concerning dll 520, although it has always been proposed that the virus could exist in
p53 competent cells but in a way that would lead to cell death by apoptosis rather than
viral replication leading to cytolysis.
One research group has suggested that the specificity of dll 20 can vary according to the
dose of the agent used. In experiments using two human hepatic carcinoma cell lines of
p53 wild-type and mutant status it has been shown that dll502 has a p53 selective effect
on cytolysis of these cells in a tissue culture model. The selective effect is reduced at
higher multiplicities of infection where the difference between the two cell lines is much
less [128]. The same group further demonstrated that dll502 could cause marked tumour
regression in the p53 mut cell lines in a murine xenograft model but had no effect in the
wild-type cell lines. These results would indicate that under the likely clinical conditions
of use, where a relatively low titre of virus would be expected to reach each tumour cell,
the effect of the virus would be p53 dependent. This p53 selectivity might be lost at
higher MOI's although this was only demonstrated in an in-vitro tissue culture model.
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The above contradictory results could be explained if it is considered that E1B-55K
protein has several functions, some ofwhich are p53 dependent and some ofwhich are
p53 independent [88]. These workers found that altering the temperature at which the
virus was inoculated into cells could affect the p53 sensitivity of the virus' actions. They
hypothesised that this indicates the E1B-55K protein has at least two separate functions
at lower temperatures, one ofwhich is independent of p53 function.
[129] provides a different explanation of the varying results described above [129]. This
group studied the infectivity of the dll520 and wild-type adenovirus in various cell lines
of known but varying p53 status. They found that the cytopathic effect of the virus
correlated with the infectivity of the virus in each cell line rather that the p53 status of
cells. They also discovered that the expression of various early adenovirus proteins was
restricted in tumour cell lines infected with dl 1520. This affected the selectivity of the
virus for various cell lines. They conclude that the infectivity and expression of early
viral products is the most important determinant of the virus selectivity for lysing cells
rather than p53 status. Mutations in other key cell cycle regulation proteins may also
affect the ability of a cell to undergo apoptosis following infection with dl 1520. It has
been found for example in experiments using mesothelioma cell lines that the efficiency
of dll 520 to kill cancer cells was higher in pl4ARFnull cell lines, and could be reduced
by transfecting wild type pl4ARF into these cell lines [130].
It is clear that the dll520 adenovirus has undergone extensive testing in a laboratory
setting. Some experiments have indicated that the virus has a selective action against
cancer cells, which is dependent on these cells having a dysfunctional p53 protein. Some
groups have called this explanation into question and have even suggested that p53
might be required to allow cell death following inoculation of the virus, ft is clear that a
full explanation of the mechanism of action of the virus will require further
investigations. Despite these ongoing controversies involving mostly in-vitro tissue
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culture work, trials involving the dl 1520 have continued in human subjects. By and large
these trials have given encouraging results as detailed below.
1.9.1 Previous in vitro studies using dl1520
The dl 1520 adenovirus has been extensively studied in tissue culture and murine
xenograft models. It has been shown that dl 1520 can grow in cell lines which lack
functional p53. The virus has been shown to replicate with efficiency comparable to
wild-type virus in tumour cell lines lacking functional p53 but with reduced efficacy (=
1%) in cell lines with normal p53 function [1], Tissue culture experiments demonstrated
no detectable cytopathic effect on normal human fibroblasts or tumour cells with
functional p53. Further studies indicated that if p53 function was restored to a previously
p53 null cell line the activity of dl 1520 was reduced [6]. The same workers further
demonstrated that it was the lack of expression ofE1B protein that led to this selectivity
by introducing this protein in a p53 competent tumour cell line resistant to dll 520. This
rendered this previously resistant cell line sensitive to cytolysis by the dll520.
The virus was also shown to cause shrinkage of human tumour xenografts grown on
nude mice in a p53 dependent manner with evidence of viral replication and spread
within p53 deficient tumours. No evidence of adenovirus survival was noted in p53
competent tumour xenografts injected with dll520 in the same experiment. Further work
demonstrated that the virus could be delivered systemically to cause restriction in tumour
growth in a p53 dependent manner and that chemotherapy can augment this restriction of
tumour growth [1]. It has further been shown in a xenograft model using
immunodeficient mice that intra venous administration of dll 520 can cause regression of
tumours and that the extent of this effect is related to the amount of virus detected in
tumours [131].
Additional evidence of the p53 selectivity of dll 520 was demonstrated in an experiment
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analysing distribution of the virus under various conditions. Using a p53 deficient cell
line, inoculation of 5% of cells prior to tumour implantation prevented tumour growth
and inoculation of only 1% of cells restricted tumour growth. In contrast, infection of
p53 competent cell lines prior to tumour cell implantation had no effect on tumour
formation [132]. Other work using lung cancer cell lines in a tissue culture model also
noted that p53 deficient cell lines were up to 10 times more sensitive that p53 competent
cell lines to the effects of dl 1520 [7]. Using dll520 against human glioma cells in a
tissue culture model again showed that the virus had almost a 10 times greater efficacy in
p53 deficient tumour cells compared to lines with a functional p53 [133].
1.9.2 Combination effects with other treatment modalities
The same group also demonstrated that dl 1520 can act in a synergistic fashion with
chemotherapeutic agents in these cell lines and that this effect was greatest using p53
deficient cell lines. Chemotherapy has been shown to act synergistically with dll 520 in
lung cancer cell lines in a p53 dependent manner [7]. It is postulated that the virus may
act to induce increases chemosensitivity, either by inducing cells to enter the cell cycle or
via a p-53 independent manner. It is also known that many standard chemotherapeutic
agents work preferentially against tumours with a functional p53 [19, 20]. The
combination of chemotherapy and dl 1520 as an anti-cancer regimen is therefore
attractive as they can act in a complementary fashion.
Radiotherapy can also augment the action of dll 520 in a murine xenograft model, again
in a p53 dependent manner. This has been demonstrated using two tumour cell lines
matched for p53 status where the virus had a greater cytolytic effect on the p53 mut cell
line [134], This study shows that radiotherapy does not hinder viral replication, probably
because the viral genome is much smaller that the human genome and therefore less
likely to sustain radiation induced damage. As radiation is most effective against cells
containing functional p53, radiotherapy is able to complement the effects of the dll 520
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virus as this acts against p53 mutant cells. The combination therapy could therefore
target both p53 mutant and wild-type cells [135].
The above results suggest that the dll520 virus has an anti-cancer cell action in many
different tumour cell lines and that the level of cell and tumour destruction is related to
the p53 status of the tumour cells concerned. Recent work has further demonstrated that
dl 1520 causes both cytolysis and apoptosis in tumour cell lines. Apoptosis is less marked
in p53 deficient cell lines, as would be predicted by the mechanism of action of the virus
[136]. This suggests that the higher replication and cytopathic effect of the virus in p53
deficient cells is due to the lack of induction of apoptosis following viral infection
thereby allowing a longer period of viral replication prior to cell death by lysis. This
cytolytic effect of dll 520 is therefore greater in p53 deficient cell lines than in p53
competent cell lines although cell death can occur in both.
1.9.3 Previous clinical studies
Dll 520 has been studied in several phase I and II clinical trials in a variety of tumour
types. Most of the studies have involved the direct intra-tumoural administration of the
virus but other methods have also been successfully utilised.
The first clinical trial of the virus was initiated in patients with recurrent squamous cell
tumours of the head and neck which were considered refractory to conventional therapy.
These tumours had all recurred following surgery and/ or radiotherapy. The virus has
been delivered by repeated intra-tumoural injection into these recurrent, refractory
tumours. A phase I dose escalation study utilizing a single dose of dll 520 delivered
intra-tumourally in these patients was successfully completed [137]. This showed that of
22 patients who received a single intra tumoural dose ofdll 520 repeated 4 weekly at
7 11
doses of 10 to 10 pfu there were no dose limiting tonicities. An objective tumour
response was seen in 5 patients with tumour stabilisation in 8 patients and the response
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duration was between 4 and 12 weeks. Evidence ofviral replication was demonstrated in
9
4 of 22 post treatment biopsies (4 of nine taken from subjects who had received > 10
pfu of virus) by immunohistochemistry and in-situ hybridisation. Some patients
exhibited gradel/11 febrile illness related to viral administration but this was self-
limiting.
In a second phase I trial involving multiple intra tumoural injection a further 10 patients
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were treated with 5 receiving 5 daily injections of 10 pfu and 5 receiving 5 daily
injections of 10' ^ pfu. No major differences in toxicity were noted from the dose
escalation trial and there was one further objective tumour response. All of the tumours
that responded had a mutant p53 sequence on gene sequencing. Evidence of viral
replication was seen in 7 of 10 biopsies by immunohistochemistry and in-situ
hybridisation. Patients tolerated the injection of virus well with no significant side
effects. It is noteworthy that the injection protocol called for the virus to be injected into
the healthy tissue surrounding tumour deposits as well as the tumour. No evidence of
damage to this normal tissue was noted. In a phase II trial 30 patients went on to receive
cycles of 5 daily injections of 10^ pfu of the virus with cycles repeated 3 weekly [138].
No additional toxicity was noted and there were 2 complete regressions and 2 partial
responses in injected tumours. Symptomatic improvement was noted in 3 patients
(improved jaw mobility n =2 and improved speech n =1).
Most recently a phase II study combining a similar regime of 5 daily injections of 1010
pfu with systemic chemotherapy (5-Fluorouracil plus cisplatin) has been completed
[139]. Patients were suffering with recurrent, refractory squamous cell tumours of the
head and neck that were otherwise considered untreatable. The trial protocol involved
cycles of five daily injections of 1010 pfu of dl 1520 directly into accessible tumour
deposits. Patients received concurrent chemotherapy of intra-venous 5-fluorouracil plus
cisplatin. Of 30 patients eligible for assessment 63% had a full or partial response to
treatment. Patients with more than one lesion suitable for injection could have a saline
46
injection into a second lesion to act as a control. Of 11 subjects in this group 9 of 11
tumours injected with dl 1520 showed a response compared to 3 of 11 saline injected
tumours. This difference is significant indicating anti-tumour activity through the dl 1520
and not simply due to the chemotherapy. No serious adverse reactions to the viral
therapy were noted in any of these trials and results are encouraging that the virus has
anti-tumour activity with no propensity to damage surrounding tissues. This trial again
demonstrated that this therapy seems to be safe with an acceptable side effect profile.
The level of clinical response was greater that would be predicted using chemotherapy
alone suggesting that the virus could be used in conjunction with standard
chemotherapeutic agents.
The virus has also been tested against various other tumour types. A trial looking at
intra-hepatic arterial infusion of the virus in patients with liver metastases from gastro¬
intestinal tumours is currently under way [140]. No significant side effects thought to be
due to the virus have been noted and in some cases there has been a reduction in the size
of tumour mass in the liver. A clinical trial looking at direct injection of inoperable
pancreatic tumours using ultrasound-guided needles is also currently ongoing [141]. A
study using intra-venous dl 1520 in patients with metastatic lung tumours is also
underway [142], These trials have produced promising data as to the feasibility and
safety of this agent used with patients with advanced, solid malignancy.
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Figure 1.3 - Example of the clinical effect of d!1520 in combination with
chemotherapy. The picture shows a cutaneous deposit of squamous cell
carcinoma from a head and neck primary cancer. Following injection with the
dl1520 virus the tumour deposit has regressed.
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1.10 Aims Of This Thesis
dl 1520 is potentially a highly selective form of viral gene therapy that might act
selectively against p53 deficient tumour cells. As more than 50% of human solid
malignancies are deficient in p53 function this agent has potential as a novel, selective
anti-cancer therapy [102]. This is a potential treatment for recurrent or systemic cancer
as the virus is selective for cells with dysfunctional p53 and should not harm normal
tissues. This selectivity is the key to the potential usefulness of the virus particularly if
systemic delivery of the virus is to be possible. If the virus were to be used to treat
disseminated disease then clearly some form of systemic delivery would be necessary.
1.11 Squamous cell carcinoma of the head and neck
Squamous carcinoma of the head and neck is a tumour type that is becoming
increasingly common. It is associated with both smoking and high alcohol intake in the
Western world and more commonly with the use of Betel nut in the Far East. Early
cancers are amenable to primary treatment with surgery, radiotherapy or a combination
of both. The disease however has a tendency to recur in the loco-regional lymph node
basin, the cervical nodes. Once this happens the outlook for the patient is poor, with a
five-year survival of only 30 %, which has remained unchanged for 30 years [143], The
disease seldom responds well to conventional chemotherapy agents and there is no
effective treatment for recurrent disease [16].
Distal metastases are rare meaning that if the disease can be controlled locally this could
lead to improved quality of life and possibly improved survival rates for patients. It is
clear that a successful treatment for locally recurrent head and neck SCC is urgently
required. D11520 could be well suited to treat disease in this area, as the cervical lymph
nodes are amenable to direct intra-viral injection. As p53 mutations are very common in
recurrent head and neck SCC this agent could be particularly suited to treating this
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disease [144],
Although it is clear that dl 1520 has an anti-cancer action there has been recent
controversy as to the mechanism ofaction of the virus. One recent paper has presented
findings suggesting that not only can dl 1520 act to destroy cells with a functional p53
but that p53 may be necessary for virus mediated cell death in a tissue culture model
[126]. Another group have suggested that the ability of the virus to cause cell death is
independent of p53 status and that damage to normal cells is possible at high MOI's
[127]. One group has suggested that the ability of the virus to infect and enter cells could
be the key to its selectivity rather than the p53 status of a cell [129]. Other workers have
demonstrated findings suggesting that the p53 selective effects of dl 1520 disappear at
high viral titres in a tissue culture model [128], It has also been suggested that lack of
function of the E1B protein could in itself inhibit viral production by restricting late viral
mRNA production [88]. These findings contradict the results ofmany experiments with
dl 1520 but despite these controversies there is little doubt that the virus has a selective
anti-tumour effect although the precise mechanism of this is not fully understood.
It is important to further investigate to what extent the virus can target tumour cells
selectively. Without this selective effect, systemic use of this virus might lead to severe
side effects if the virus can replicate within and destroy normal cells with a functional
p53. If the agent were however truly p53 selective it would have great potential as an
anti-cancer agent that is targeted specifically to tumour cells. Further clarification is
desired as regards many of the above points. This is especially so as concerns the p53
and therefore tumour selectivity of the virus. The work reported in this thesis can be
divided into the clinical trial undertaken and laboratory based experiments.
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1.12.1 - Clinical trial
A clinical trial was devised to further investigate:
The mechanism of action of dll520
The p53 specificity of the virus in vivo
Optimisation of intra-tumoural viral delivery
Tolerance of administration of dll520 in a select patient group
Immune cell response to the virus
Level of tumour necrosis following viral administration
1.12.2 - Laboratory based experiments
Laboratory experiments were performed to further clarify:
• The mechanism of action of dll520
• The p53 specificity of the virus both in vitro and in vivo
• Optimisation of intra-tumoural virus delivery
• The effect of combining the virus with other standard chemotherapeutic agents
There follows below a synopsis of the clinical trial and laboratory experiments to further
investigate the specificity and activity of dl 1520 particularly as this relates to p53 status
of cells. A tissue culture model with cell lines matched for p53 status was used to study
the effect of combining chemotherapy with dll 520 in-vitro. A murine xenograft model
was designed to investigate the effect of intra-tumoural injection of dll 520 in different
cell lines matched for p53 function.
1.13 Clinical trial
A clinical trial was devised to explore the p53 selectivity of dll 520 following a single
intra-tumoural injection into oral cancers at set points prior to the tumour's resection.
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Virus was injected into half of each tumour and saline into the other half to act as a
control. An injection of virus into an area of normal tissue within the oral cavity was also
made. This was made into an area of grossly normal tissue not affected by tumour or any
other lesion. Following resection samples were analysed for viral replication and spread;
oncolytic effect; mechanism of cell death and expression of p53 and p21 protein. Results
were correlated with p53 status determined by gene sequencing of tumour samples taken
prior to viral injection.
The effect of the injection of the virus on the patients' immune system was also
investigated. FACS analysis ofwhole blood samples to detect various cell markers was
undertaken before and after the viral injections. This allowed measurement of various
immune cell sub-sets in the circulation to determine what effect the virus has on these
following intra-tumoural injection.
1.13.1 Laboratory based experiments
1.13.2 Effect of combining d!1520 with chemotherapeutic agents
Many human malignancies are treated with systemic chemotherapy either as adjuvant
treatment to a primary therapy or to treat recurrent or metastatic disease. We wished to
ascertain the effect of using dl 1520 as an anti-cancer agent along with chemotherapy. It
is important to determine if the virus could act in synergy or in an additive fashion with
standard chemotherapeutic agents or if there was any evidence of antagonism. A tissue
culture model was devised using cell lines matched for p53 status. These were exposed
to various concentrations of dl 1520 for different time points to allow for any possible
differential effect caused by replication over time. Cells were then treated with the
chemotherapy agents at various concentrations. Clonogenic analysis was used to
determine levels of cell kill at each level of viral load and concentration of
chemotherapy. Results looking at the clonogenic survival of sub-cultures for each value
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were determined against controls with no virus or chemotherapy agent.
1.13.3 Effect of a single intra-tumoural injection of dl1520 in a xenograft
model
An experiment to investigate the effect of a single intra-tumoural in a murine xenograft
model was devised. Cell lines matched for p53 status were used to grow xenografts to a
size of approximately 6mm. These were injected with a single injection of dl 1520 into
all 4 quadrants of the tumour to investigate the effect of p53 status on viral distribution
and replication. Tumours were harvested at various time-points following the injection
to look at effects due to replication as well as distribution of the virus.
1.13.4 Effect of varying the carrier medium on distribution of dl1520
adenovirus on a single intra-tumoural injection of d!1520 in a xenograft
model
Previous work has shown that following injection of dl 1520, both in xenograft models
and whilst treating human subjects, the virus tends to be restricted to an area between the
necrotic centre of the tumour and the viable tumour tissue. This is thought to be the
interface where the cytolytic effect of the virus is at its maximum. If the virus could be
distributed more fully throughout the tumour it is possible that this would increase the
biological effect of the virus as its activity would not be restricted to this area.
Several agents are in use clinically which could in theory increase the distribution of an
intra-tumurally injected agent. Hyaluronidase is an enzyme that acts to break down
hyaluronic acid, an important constituent of interstitial ground substance. This causes
elements of the connective tissue to liquefy, aiding the distribution of any agent injected
in conjunction with the hyaluronidase. Hyaluronidase is in use clinically to increase the
spread of local anaesthetic agents injected subcutaneously and is known to be effective
in this action [145]. Lignocaine is a commonly used local anaesthetic agent that acts by
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blocking sodium channels. This also has the effect of dilating arterioles thus causing
increased local blood flow by vasodilatation. Increased local blood flow could lead to
enhanced distribution of an intra-tumurally injected agent such as dl 1520.
An experiment was devised to measure the effect of varying the carrier medium on the
distribution ofdl 1520 following a single intra-tumoural injection in the xenograft model.
Hyaluronidase was used as one agent as its effect in breaking down ground substance
may increase viral distribution. Lignocaine was also used as its vasodilatory effect may
act to increase viral distribution. A single injection of dl 1520 was administered into all
four quadrants of tumour xenografts. Tumours were harvested at set points following
this injection and imunohistochemical staining used to determine the distribution of
virus at these time points.
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CHAPTER 2
A CLINICAL TRIAL INVOLVING A SINGLE PRE¬
OPERATIVE INJECTION OF d!1520 IN
RESECTABLE SQUAMOUS CELL MALIGNANCY
OF THE HEAD AND NECK
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A Clinical Trial Involving A Single Pre-operative Injection Of dl1520 In Resectable
Oral Squamous Cell Malignancy
2.1.1 Background
There have been several clinical trials involving the administration ofdll520 to treat
various cancer types including head and neck, ovarian and various gastro-intestinal
malignancies [75, 146]. All such trials have involved patients with either locally
advanced or metastatic disease not treatable by conventional means. Methods ofvirus
administration have included direct intra-tumoural injection, intra-peritoneal infusion,
intravenous infusion and infusion into the hepatic artery to treat hepatic metastases.
Several of these studies have shown encouraging results with the treatment well tolerated
and showing efficacy in many cases in terms of regression or stabilization of disease.
Side effects have been minimal with none of the above trials seeing a dose limiting
toxicity with the agent. Some patients have suffered symptoms such as fever, malaise,
nausea and headache, which are associated with adenoviral infection, but overall the
treatments have been well tolerated.
In the field of head and neck cancer both phase I and phase II trials involving the virus
alone and a phase II trial involving the virus plus chemotherapy in patients with recurrent
tumours considered unbeatable by conventional methods have been successfully
undertaken [137, 139]. When used as a single agent there was evidence of a p53
selectivity of action of dl 1520 as tumours that responded to the treatment were found to
have mutant p53. In the trial combining chemotherapy with intra-tumoural injection
there was no such selectivity demonstrated. This could be predicted as the chemotherapy
agents used, cisplatin and 5-fluoruracil, are most effective in p53 competent tissues. In
tumours with wild-type p53 therefore one could surmise that the chemotherapy would be
more effective than in p53 null tissues where the dl 1520 would be most effective.
Our study aimed to address the following main points:
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1. To determine if the virus is selective for survival and replication in p53 mutant tumours as
opposed to p53 wild type tumours in the clinical setting
2. To determine the level of viral spread and replication within such tumours.
3. To determine the effect of the virus on normal tissues following a direct viral injection
To answer these questions the following points were addressed:
1. What is the frequency ofmutation of the p53 gene in tumour and normal tissue?
2. How does the presence of virus vary according to the p53 status of both normal and tumour
tissues and to what extent can the virus spread through such tissues?
3. What are the levels of virus induced apoptosis in normal and tumour tissues following virus
injection?
2.1.2 Viral replication
Much is known about the capacity of dl 1520 to replicate in cell lines and tumour
xenografts from laboratory based studies, as detailed above. Difficulties have however
been encountered in attempts to ascertain accurate data as to levels ofviral replication
and spread in various tissues and how this relates to tissue p53 status in the clinical
setting. In the various clinical trials involving head and neck malignancy for example
there were difficulties in obtaining representative tissue biopsies from the heterogeneous
tumour samples. Tumours in this trial were recurrent and usually large making
representative sampling difficult. The biopsies taken were small trucut biopsies that were
not necessarily representative of the relatively large tumour masses being sampled.
Analysis of these samples from these trials has so far given little information as to p53
specificity of dll520, levels of viral replication, spread within tumours and mechanism
of cell death in the clinical model [131]. Biopsies have shown evidence of viral presence




Little is known about the propensity of the virus to spread within tumours following
injection. In-vivo studies in a murine xenograft model have suggested that the virus can
spread following injection. In clinical use there would be many other factors that would
influence this such as the physical properties of the tumours and the host immune
response. Any spread of the virus within tumour tissue could be beneficial in allowing
widespread tumour cell kill ofwidespread disease even if this tissue was not directly
injected. If the virus was capable of spreading within normal tissue however this could
lead to collateral damage of healthy tissues surrounding the treated tumour so adversely
affecting the side effect profile.
To date, studies of intra-tumoural injection of the virus in head and neck tumours have
dealt with tumours that have been previously treated with radiotherapy, which usually
leads to tissue fibrosis. In effect the tumours were surrounded by the physical constraints
of fibrotic tissue. This may have had the effect of preventing optimal distribution of the
virus. The tumours were generally large which meant assessment of spread was difficult,
as only small trucut biopsies were available for analysis.
2.1.4 Effect of d!1520 on normal, non-malignant tissue
Little is known about the clinical effect of injecting dl 1520 into normal healthy tissue. In
theory any such injection would lead to only a very localized controlled apoptotic cell
death without viral replication and spread as the action of the virus would be curtailed by
the function ofp53 in healthy tissue. Evidence of cytolysis of some wild-type cell lines
has been noted in previous laboratory studies. Prior clinical trials of injection of dl 1520
in recurrent head and neck tumour masses have involved an injection into tissues
surrounding the tumour masses i.e. at the interface between tumour and healthy tissue
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surrounding the tumour [139]. There was no clinical evidence of harm to these
surrounding tissues in terms of ulceration or tissue destruction, which supports the
hypothesis that the virus should do these tissues no harm. No biopsies of these normal
tissues however have been analyzed for viral spread or p53 status.
We wished in this trial to determine the effect of a direct injection of dl 1520 into normal
tissues to see if the virus could harm normal tissue or if the effect would be contained. It
is clearly important that further information as to the ability of the virus to replicate and
spread within both malignant and normal tissue is obtained. Ideally these tumours would
not have had previous radiotherapy which could limit the spread of the virus. This
information needs to be correlated with p53 status of these various tissues.
2.1.5 Immune response
Prior studies have demonstrated a humoral response to adenoviral injection, which was
present following intra-tumoural injection of the virus [137]. Administering a virus into
a patient is likely to stimulate both a humoral and cell mediated immune response as the
body recognises the virus as a pathogen, [147]. Such an immune response could limit the
effectiveness of viral therapy particularly where multiple doses are administered, as
circulating anti-bodies would quickly destroy the virus. A strong immune response
against adenovirus could curtail efforts to deliver a viral therapy systemically.
Localised immune cell infiltration into tumour however could lead to enhanced tumour
cell destruction. A gene therapy study looking at adenoviral injection into breast and
melanoma cutaneous deposits has demonstrated cytolysis associated with immune cell
infiltration, although it was unclear whether the adenovirus or the gene product
subsequently produced was the cause of this [148]. We wished to investigate in more
detail the immune response generated against the virus following a direct intra-tumoural
injection by analysing white cell counts before and after injection of the virus.
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2.1.6 Mechanism of cell death
It is postulated that the dll520 virus should cause cell death predominantly by cytolysis
following viral replication in tissues which are permissive for such replication i.e. p53
null cells. It is known that dll 520 can also cause apoptosis and this would be predicted
in p53 competent tissue. It is therefore important to know to what extent the virus can
generate apoptotic cell death in both healthy and cancerous tissue and how this relates to
p53 status of these tissues.
2.2 Trial design
In the hope of answering the above questions a clinical trial was designed and
implemented. The trial was devised to investigate a single intra-tumoural injection of
dll 520 into tumour tissue and normal tissue in patients with squamous carcinoma of the
oral cavity was undertaken. Patients due to have excisional surgery for intra oral
squamous carcinoma were recruited into three cohorts who received a direct intra-
tumoural injection of virus at either 1, 3, or 14 days prior to excision of the tumour.
Patients also received an injection of dll 520 into normal intra-oral tissue at this time.
The site of this normal tissue injection was buccal mucosa in an area of grossly normal
tissue not involved by tumour or any apparent field change within the mouth. The Local
Research Ethical Committee, the Gene Therapy Advisory Committee and the Medicines
Control Agency approved the experimental protocol.
Surgery was undertaken as per the normal protocol for such cases, involving excision of
the primary tumour and in most cases the cervical lymph nodes from the side of the neck
closest to the tumour [149]. A biopsy of the area of normal tissue injected with the virus
was taken at this time. Following surgery the tumour and the biopsy of the injected
normal tissue were analyzed to look at viral replication and spread within the samples.
The samples were also tested for p53 status; p21 status and the level and mechanism of
cell death. Peripheral blood counts including lymphocyte counts were taken prior to
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injection and immediately prior to surgery.
By analysing tumour samples at the three time points it was hoped to determine levels of
replication of dl 1520 virus by looking at the difference between levels of virus at 24hrs,
72hrs and 14 days. Earlier studies utilizing a mouse xenograft model have demonstrated
that in this model the virus peaks at a maximal level at around 72 hrs and then levels
would be expected to tail off by day fourteen. This would be predicted by the replication
cycle of the adenovirus [79].
This study was designed to give important information about the ability of the virus to
survive and replicate in both p53 deficient and p53 functional tumour tissue and normal,
non-tumour tissue and allow us to correlate this with cell death of both tumour and
normal tissue. It also allowed us to determine the nature of the body's immune response
to viral injection both systemically and within the tumour itself.
2.3 Oral squamous cell carcinoma
All the patients recruited into the trial were suffering from oral squamous cell carcinoma.
These tumours have frequent p53 mutations and are accessible for direct injection and as
such were a suitable model for this study [90]. Oral SCC is a relatively uncommon
tumour in the West but is increasing in incidence, especially amongst females and
younger adults < 40 yrs [91, 150]. The disease can be aggressive and often recurs loco-
regionally following primary treatment. Distal metastases are however rare and this
tumour could be an ideal candidate for intra-tumoural therapies such as dl 1520 as both
the primary tumour and likely sites of recurrence are amenable to direct injection.
Oral SCC is thus an ideal candidate for investigation ofdll520 viral gene therapy. The
tumour is amenable to injection and is suitable for the assessments required, as detailed
above. There is a need for an effective salvage treatment for this form of cancer as if the
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tumour recurs following primary treatment it is not usually amenable to further standard
treatments [15, 151]. Targeted gene therapy strategies such as dll520 can potentially
address the problems posed by such tumours.
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PRE-OPERATIVE INJECTION OF dl1520
ADENOVIRUS - RECRUITMENT AND EVENTS
3.1 Recruitment criteria
Patients were eligible to be enrolled into the trial if they satisfied the following criteria:
3.1.1 Tumour status
1.Tumours had to be primary squamous cell carcinomas of the head and neck. All
patients recruited in fact had cancer of the oral cavity including oropharynx.
2. The tumour had to be amenable to complete surgical resection.
3. The tumour had to be appropriately treated by surgical resection (as determined by the
consultant in charge of each case).
3.1.2 Patient characteristics
1. Patients had to be 18-75 years of age.
2.Consent for study participation was given before screening and treatment, on an
approved informed consent form.
3. Hepatic AST and ALT < 2.5-fold upper limit of normal; total bilirubin within normal
limits; PT/ INR = 2.0 and PTT within normal limits.
4. Karnofsky Performance Status > 70%.
5. For sexually active males and females of reproductive age a suitable contraceptive had
to be used during the conduct of the trial and for three months afterwards.
3.1.3 Exclusion criteria
Patients with any of the following were excluded from the study.
1. Ulceration and/or necrosis of the injected tumour might lead to difficulties in surgical
resection, in the judgment of the P.I. and/or attending surgeon.
2. Invasion of the tumour into the carotid artery or its sheath.
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3. Chemotherapy within the last three weeks (six weeks for nitrosoureas or mitomycin-
C).
4. Radiotherapy to the target tumour site within the last three weeks.
5. Concomitant haematological malignancy (e.g. chronic lymphocytic leukaemia, non-
Hodgkin's lymphoma).
6. Impending airway obstruction or other condition requiring urgent (predicted within
two weeks) tumour debulking.
7. Pregnant or lactating females.
8. Maximal tumour diameter of 6cm.
9. Treatment with any other investigational therapy within the last six weeks.
10. Viral syndrome diagnosed within the last two weeks.
11. Ongoing active infection, including human immunodeficiency virus.
12. Patients with prior therapeutic adenovirus treatment.
3.2 Sample size
A sample size of 15 patients was recruited into the study. This was determined by the
logistics of the supply of the dl 1520 virus that was made available for this project by the
sponsoring company. It was felt that this number would give sufficient numbers of the
groups of patients required for analysis.
3.3 Screening investigations
A checklist of screening and pre-treatment evaluations follows:
1. Signed Local Research Ethics Committee approved informed consent
2. Testing of tumour biopsy by immunohistochemistry (IHC) and p53 gene sequencing for p53
status (results not required prior to patient's treatment with dll 520).
3. Complete medical history
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4. Complete physical examination, including vital signs, weight, and height
5. Karnofsky performance score
6. Hematological tests, including prothrombin time (PT) and INR, and partial
thromboplastin time (PTT) (Reference Section 10.1.1)
7. CD3, CD4, CD8 and total lymphocyte counts
8. Serum chemistry tests (Reference Section 10.1.2)
9. Plasma antibody to type 5 adenovirus (neutralizing)
10. Archival plasma sample
11. Electrocardiogram (12-lead)
12. Chest x-ray
13. Delayed-type hypersensitivity skin testing using a subcutaneous injection of
Multitest CMI (testing response to: tuberculin, tetanus, diptheria, streptococcus, glycerin,
Candida, trichophyton and porteus antigens).
14. Secondary diagnoses
15. Baseline medical events, including signs, symptoms, and illnesses
3.4 T reatment protocol
All patients were treated with 1010 pfu of virus into the tumour and a further 10!0 pfu of
virus into an area of normal intra-oral tissue, (buccal mucosa). The patients were
enrolled into the study and then randomized to receive surgery for tumour excision and
normal tissue biopsy at specified timepoints following viral injection. This involved
three groups of five patients being allocated to receive an injection ofdll 520 virus at
fixed times prior to surgery as follows:
• 5 patients received a dll520 injection 24 hours (+/- 6 hours) prior to surgery.
• 5 patients received a dl 1520 injection 72 hours (+/- 24 hours) prior to surgery.
• 5 patients received a dll520 injection 14 days (+/- 1 day) prior to surgery.
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The injection protocol called for the tumour to be divided into halves. One half of the
tumour was injected with virus and the other half (control half) was injected with diluent
only. The volume of liquid injected into each hemi-tumour was calculated as 15% of the
entire tumour volume. The volume injected into the normal tissue was lOOpl in each
case. Tattooing was used to mark the areas of each tumour injected and the area of
normal tissue injected so as to ensure the correct areas were sampled in each case. 1%
lignocaine could be administered in to the tumour and/ or normal tissue prior to the
injection as a local anaesthetic (see figure 3-1).
68
Figure 3.1 - injection protocol
Normal tissue Tumour
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Following the injection patients were monitored for any adverse events and were kept in
hospital for a minimum of 24 hrs. Both injection sites were inspected prior to discharge
for evidence of inflammation or necrosis. Patients underwent surgical resection of their
tumour at a given time-point following the injection of dl 1520 (24hrs, 72hrs or 14 days).
Immediately prior to surgery blood samples were drawn for CD3, CD4, CD8 and total
lymphocyte counts. A biopsy of the area of normal tissue injected with dl 1520 was also
taken at this time. At the time of surgery each tumour specimen was divided into an Onyx
injected half and a control or diluent injected half and from each a sample of tumour was
taken for a frozen specimen. The remainder of each hemi-tumour was fixed in formalin as
per the normal histology protocol.
Following surgery the patients received the normal standard of care following each
operation. A note of adverse events was taken and patients were reviewed regularly
following recovery.
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CHAPTER 4 - MATERIALS AND METHODS
CLINICAL TRIAL
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4 Materials and methods
4.1 Protocol for lymphocyte counts - whole blood
500 pi ofwhole blood was aliquoted into 5 ml analysis tubes. Anti-bodies were supplied
by Becton-Dickinson. To each of 8 tubes 10 pi of antibodies were added as follows:
Tube 1 - both colour irrelevant i.e. PE/ FITC.
Tube 2 - CD3/ PE -ve.
Tube 3 - CD4/ FITC -ve.
Tube 4 - CD3/ CD4.
Tube 5 - CD2/ CD8.
Tube 6 - CD4/ CD 14.
Tube 7 - CD3/ RO.
Tube 8 - CD3/CD56.
Tubes were incubated at 4 °C for 20 minutes. 2ml ofFACS lysis solution (1:10 dilution
dH20) was added and samples left for 10 minutes at room temperature. Samples were
then centrifuged at 1200rpm for 5 minutes, the supernatant aspirated and the pellet
resuspended. 2ml PBS was added and the samples were re-centrifuged at 298 RCF for 5
minutes. The supernatant was again aspirated and the pellet resuspended in 500pl PBS.
FACS (fluorescence-activated cell sorter) analysis was performed on each sample using
a Becton Dickinson FACS cytometer.
4.2 Sample processing
4.2.1 P53 gene sequencing
Tumour biopsies for gene sequencing were immediately flash frozen in liquid nitrogen.
Gene sequencing was performed at Virco Laboratories, Baltimore, USA using the
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genechip micro array. Samples from the normal tissue biopsies were not assessed for
gene sequencing as the samples taken were small and it was felt that there was not
enough tissue to spare to allow for gene sequencing. Probes on the array are arranged in
sets of five. Each probe in the set is perfectly complementary to the reference sequence
except for a mismatch position, called the "substitution position". At the substitution
position, each of the four possible nucleotides (A,C,G,T) and a single base deletion are
represented in the probe set. Assay conditions optimise hybridisation of the fluorescently
labelled DNA target to the probe that best matches its sequence. The array contains
probes that can test the entire 1.2-kb coding sequence of the TP53 gene, including a part
of the intron/exon boundaries [152]. This hybrid yields higher fluorescence intensity
relative to the other four target probe hybrids in the set. There are probe sets
complementary to every base in the target gene, so each base along the genejs examined
for the presence ofmutant sequence. The assay has been shown to have a concordance of
92% when compared with traditional techniques, and could detect as little as 1%
mutated DNA [153].
4.2.2 Normal tissue biopsy and excised tumours
At the time of surgery the excised tumours and the biopsy ofnormal tissue were divided
into two halves to represent the dl 1520 injected normal tissue, the dl 1520 and saline
injected hemi-tumours. The normal tissue sample was bisected and from the cut face of
each half a slice of tumour was removed. Each of the three samples was placed in a
cryomould half filled with OCT solution, which had been briefly immersed in liquid
nitrogen. The sample was then placed in the cryomould, covered in OCT and then frozen
in liquid nitrogen for 30 seconds. The remaining tissues were fixed in formalin and
processed in the normal fashion for histological, immunohistochemical and in-situ
hybridisation analysis.
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4.3 Protocol for in-situ hybridisation for adeno-virus DNA r 154]
Paraffin sections were dewaxed in three changes of xylene for 5 minutes each and
rehydrated through a series of 100%, 90% and 70% ethanol and distilled water. The
slides were then dried in an incubator at 37°C for 10 minutes. They were then immersed
in protienase K buffer at 42°C for 2 minutes. Slides were fixed in 4%formaldehyde in
PBS for 5 minutes and dehydrated through dH20, 70% ethanol and 100% ethanol before
being dried at 37°C for 10 minutes. Each run was repeated to confirm accuracy. Both
positive and negative control slides were included, positive slides being provided by the
test manufacturer and archival oral SCC specimens were used as negative controls.
40pl of biotinylated adenoviral DNA probe was applied to each section and a coverslip
applied which was sealed with cow gum. Hybridisation was carried out overnight at
37°C. Each coverslip was removed in PBS and the slides washed for 5 minutes. 100pl of
post-hybridisation reagent was applied to each section for 10 minutes at 37°C and slides
were rinsed in two changes of PBS.
Anti-biotin/ alkaline phosphatase conjugate diluted 1:200 with PBS with 0.1% Tween 20
was applied to each slide and incubated for 2 hours at room temperature and slides were
rinsed in PBS for 2 minutes. The slides were rinsed in colour development buffer twice
for 5 minutes. NBT/BCIP was used for detection and sections were treated for 45
minutes at room temperature until colour developed. Slides were counter stained with
nuclear fast red and rinsed in H20. Sections were dehydrated through 70%, 90% and
100% alcohol prior to being immersed in three changes of xylene. Sections were
mounted using permount.
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4.4 Protocol for hexon stain for adenoviral protein expression (Heise 1995,
protocol obtained from Onyx Pharmaceuticals)
Paraffin sections were dewaxed in three changes of xylene for 5 minutes each and
rehydrated through a series of 100%, 90% and 70% ethanol and distilled water.
Immersing the slides in 3% hydrogen peroxide in methanol for 45 minutes quenched
endogenous peroxidase activity and the slides were rinsed in two changes ofPBS. All
samples were analysed twice. dll520 injected murine xenograft samples harvested from
prior experiments were used as a positive control and archival oral SCC samples as a
negative control.
The sections were then treated with protease (1.7mg/ ml in PBS) for 20 minutes in a
humidified chamber at 35 0 C and the slides were rinsed in two changes ofPBS. Casein
solution was used to block non-specific binding (diluted 1:10 in PBS). The primary anti¬
body mouse anti-adenovirus monoclonal antibody Iglk isotype (Chemicon) was initially
used at a dilution of 1:1000 and 100 pi was added to the section and a coverslip added.
This was incubated for 45 mins in a humidified chamber at 35 0 C and slides were rinsed
in two changes ofPBS. For the tumour biopsies this was found to give insufficient
sensitivity and the concentration of anti-body was increased to 1:500.
Subsequent antibodies were provided from the Biogenex Super Sensitive
Immunodetection System, Biogenex. 100 pi of a biotinylated secondary antibody was
added to each section and incubated for 20 mins at room temperature and slides were
rinsed in two changes ofPBS. Streptavidin-horseradish peroxidase conjugate (100 pi)
was added to each section and incubated for 20 mins at room temperature and slides
were rinsed in two changes ofPBS. DAB was used as a chromagen with 100 pi added to
each section for 8 mins. Slides were then rinsed in distilled water, counter-stained in
Mayer's hematoxylin for 2 mins and dipped in Ammonia water for 10 seconds. Sections
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were dehydrated through 70%, 90% and 100% alcohol prior to being immersed in three
changes of xylene. Sections were mounted using permount.
4.5 Protocol forTunel in-situ cell death detection [ 155]
Paraffin sections were dewaxed in three changes of xylene for 5 minutes each and
rehydrated through a series of 100%, 90% and 70% ethanol and distilled water. 50 pi of
proteinase K was applied to each section, which was covered with a coverslip, and
incubated for 20 mins at 37 ° C. Slides were rinsed in two changes of PBS. Endogenous
peroxidase activity was blocked using 0.3% H202 in methanol and cells were initially
permeabilised using 0.1% Triton X-100 in 0.1% Sodium citrate at 4°C for 2 mins. This
was found to lead to insufficient sensitivity and the step was modified to have 5 mins
permiabilisation at room temperature. All samples were analysed twice with irradiated
mouse tails used as positive controls and normal skin as negative controls.
Slides were rinsed in two changes ofPBS and 50 pi ofTunel reagent was added and a
coverslip applied. Slides were incubated in a humidified chamber for 60 mins at 37 0 C.
50 pi of converter POD was applied to each section coverslip applied. DAB was used as
a chromagen with 100 pi added to each section for 10 mins. Slides were then rinsed in
distilled water, counter-stained in Mayer's hematoxylin for 2 mins and dipped in
Ammonia water for 10 seconds.
4.6 Protocol for immunohistochemistry stain for P21/ P53 r 156]
Paraffin sections were dewaxed in three changes of xylene for 5 minutes each and
rehydrated through a series of 100%, 90% and 70% ethanol and tap water for 2 minutes
each. Endogenous peroxidase activity was quenched by immersing the slides in 0.1 %
hydrogen peroxide in distilled water for 30 minutes and the slides were rinsed in two
changes ofPBS for 5 mins each. Antigen retrieval was performed by treating the slides
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in a 650W microwave oven for 15 minutes whilst immersed in sodium tricitrate.
Vectastain ABC kits were used to provide link antibodies. Each section was covered
with 100 pi of blocking serum and was incubated in a humidified chamber for 20 mins at
RT.
This was tapped off each section in turn and 100 pi of primary antibody added as
follows:
For p53 stain the antibody was used at a dilution of 1/1000 in PBS for 45 minutes at
RT.
For p21 stain the antibody was used at a dilution of 1/100 in PBS for 1 hour at RT.
Sections were rinsed in two changes ofPBS and incubated with 100 pi of biotinylated
antibody in a humidified chamber for 30 mins at RT. They were then rinsed in two
changes ofPBS. 100 pi ofABC solution was added to each section and these were
incubated in a humidified chamber for 30 mins at RT and then rinsed in two changes of
PBS. DAB was used as a chromagen with 100 pi added to each section for 8 mins.
Sections were rinsed in PBS and each section was covered with 100 pi of blocking
serum and was incubated in a humidified chamber for 20 mins at RT. Antibody was
applied as described above. Sections were rinsed in two changes ofPBS and incubated
with 100 pi of biotinylated antibody in a humidified chamber for 30 mins at RT, before
being rinsed in two changes of PBS. 100 pi ofABC solution was added to each section
and these were incubated in a humidified chamber for 30 mins.
Slides were then rinsed in distilled water. For p53 and p21 they were counter-stained in
Mayer's hematoxylin for 2 mins and dipped in Ammonia water for 10 seconds. Sections
were dehydrated through 70%, 90% and 100% alcohol prior to being immersed in three
changes of xylene. Sections were mounted using permount. All analyses were performed
twice. Irradiated mouse tail was used as a positive control and normal skin as a negative.
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CHAPTER FIVE
CLINICAL TRIAL - RESULTS
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5.1 General
5.1.1 Administration of the virus
All patients tolerated the injection ofvirus well. In 4 patients the injections were made
whilst the patient was under general anaesthetic. In the remaining 11 patients the
injections were made whilst the patient was conscious. Local anaesthetic was used in 9
out of 11 of these patients. Patients experienced mild to moderate discomfort but in no
cases did this interfere with administration of the virus.
5.1.2 Adverse events
Adverse events are summarised in table 5.1 below. No serious adverse events thought to
be due to the virus were noted. One patient developed painless swelling at the injection
site 3 days following the injection. Anti-biotics were administered for a suspected
bacterial infection and the swelling settled. No evidence of viraemia such as pyrexia or
rigours was noted and there were no allergic reactions in any patient. Other
complications were noted in this series including one loss of free tissue transfer, 4 cases
of bronchopneumonia, one fistula formation and one case of electrolyte imbalance. None
of these were thought to be related to the administration of the dl 1520 adenovirus. These
complications were in keeping with post-operative complications following this type of
major surgery.
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Table 5.1 - adverse events
Nature of adverse event Freauencv Relationship to virus
Swelling at injection site 1 possible
Flap loss 1 unlikely
Fistula formation 1 unlikely
Electrolyte imbalance 1 unlikely
Bronchopneumonia 4 unlikely
5.1.3 Clinical effect - tumour
The injected tumour samples were inspected regularly following injection and at the time
of resection for any alteration in gross appearance. No gross changes were noted in
tumour specimens following viral or saline injection. Tumours were assessed for
decrease in size, inflammation or increased ulceration following the viral injection but
there were no changes visible to the naked eye in either the dl 1520 injected or saline
injected hemi-tumours.
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Figure 5.1 - resected tumour sample following injection of d!1520 72hrs
previously
Figure 5.2 - buccal mucosa i.e. normal tissue following injection of dl1520
72hrs previously
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5.1.4 Clinical effect - normal tissue
No permanent gross changes were noted in normal tissue specimens following viral
injection. The area ofbuccal mucosa was assessed for signs of inflammation or
ulceration following injection. In one case there was a transient inflammation of the
injection site 72hrs following injection but no other changes visible to the naked eye in
the dl 1520 injected areas were noted. Figure 5.2 illustrates a typical injection site
tattooed with blue dye for accurate biopsy of the injected area.
5.2 P53 sequencing of tumours
Of 15 biopsies taken for p53 sequencing, 14 were acceptable for gene sequencing. One
sample was too small for accurate sequencing and was therefore unsuitable. The results
are as noted below showing that 4 out of 15 biopsies showed a wild-type gene sequence
with 10 showing one of a variety ofmutations (see table 5.2). Also shown is the score
for each sample for immunohistochemistry for p53 protein (see table 5.3). Mutations
were cross referenced with a p53 mutation database, the International Agency For
Cancer Research, to determine if the mutations had been described previously and if so
what their likely effect was on the production or function of the p53 protein. Where
known the site of the codon affected by the mutation was also described by cross-
referencing with recent work looking at the structural significance of p53 DNA
mutations on the eventual p53 protein formation [157], All the mutations found had been
previously noted in other solid tumours. All the mutations described were sufficiently
important to disrupt the function of the p53 protein.
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Table 5.2 - p53 gene sequencing
Patient
Number







Codon 215 from AGT
(serine) to ATT (isoleucine)






Codon 255 from ATC
(isoleucine) to AGC (serine)






Codon 163 from TAC
(tyrosine) to TGC (cysteine)





















Codon 159 from GCC
(alanine) to GTC (valine)
and codon 342 from CGA









Table 5.2 (continued) - p53 gene sequencing
Patient
Number





































Codon 175 from CGC









Codon 179 from CAT







All the mutations found had been previously described in human malignancy. They were
all described as being likely to adversely affect the function of the p53 protein. The
commonest mutations found involved missense mutations (n=7). Four of these were in
the DNA binding domain, 2 were in the core domain and one was at codon 225. There
were three mutations affecting introns 5,6 and 8 so as to alter the pattern ofmRNA
splicing which would have a significant effect on p53 formation. It is therefore likely
that in all cases where a p53 mutation was noted in the tumour biopsy then the function
of the p53 protein produced would be defective[ 158-161].
Table 5.3 - shows the correlation between the gene sequencing results from tumour
biopsy and the expression ofp53 found with immunohistochemical staining. The
immunohistochemistry scores were derived from assessing a combination of the sum of
% of cells positive within the sample and the intensity of the staining as follows:
% cells staining positive: Nil 1-20% 20-80% >80%
Score 0 1 2 3
Intensity of cell staining: Nil Weak Moderate Strong
0 1 2 3
For each specimen therefore there is a minimum score of 0 and a maximum of 6. A
minimum of five high powered fields (hpf) for each specimen were assessed. The
samples were controlled for cell density as assessments were made of tumour tissue only
which would be expected to have a similar density of cells. As the assessment was made
on a percentage of cells being positive, the absolute cell density was not crucial to this
score.
It can be seen that all the samples with a wild-type gene sequence were negative for p53
expression with immunohistochemistry. This would be expected as negative staining for
p53 generally indicates a normal p53 protein, although excessive amounts of normal
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protein can be detected by immunohistochemistry [162, 163]. Of the tumour samples
where gene sequencing indicated a p53 mutation, 8 out of 10 stained positive with
immunohistochemistry. There are several explanations for this discrepancy that are
discussed in the next chapter.
Of the normal tissue biopsies 8 out of 15 stained positive for p53 mutation. This could
indicate a possible field change in these areas, as it is known that p53 overexpression is
common in areas of normal mucosa adjacent to oral cancers [4]. This might indicate that
these areas harboured cells with the potential to undergo malignant change, although the
significance ofp53 overexpression in normal mucosa is not fully understood [3].
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5.3 Microscopic appearance of tissue
5.3.1 Normal tissue
The 15 normal tissue biopsies were similar in appearance viewed microscopically. There
was no evidence of tissue necrosis or ulceration in the areas sampled. A lymphocytic
infiltrate was noted in all the samples both within the epithelial layer and deeper into the
muscle (see figure 5.5). This infiltrate was a constant finding at all three timepoints
assayed and no difference was found between viral injected and control samples. It is
known that oral SCC is often associated with a lymphocytic infiltrate and it is not clear if
treatment with the dl 1520 adenovirus has any effect on this [164].
5.3.2 Tumour tissue - dl1520 injected
The tumour samples were heterogeneous in appearance with samples displaying a
spectrum of tumour patterns and differing amounts of other tissues such as muscle and
salivary glands. A marked lymphocytic infiltrate was noted in all specimens at all
timepoints assayed as noted above. There was no evidence of grossly increased tumour
necrosis in the dll520-injected specimens compared to the saline injected areas.
5.3.3 Tumour tissue - saline injected
The appearance of these samples was similar to that of the dll520 injected samples.
Again there was an obvious lymphocytic infiltrate but no evidence of gross tissue
necrosis.
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Figure 5.3 - H and E of normal tissue biopsy showing lymphocytic infiltrate
H and E of dl1520 injected tumour tissue sample showing lymphocytic
infiltrate.
90
H and E of saline injected tumour tissue sample showing lymphocytic
infiltrate
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5.4 Adenoviral replication and distribution - detection of d!1520
Samples were assessed for the presence or absence of the dll520 adenovirus as
described above using both in-situ hybridisation (ISH) and immunohistochemistry
(IHC). They were further analysed to determine the density of cells positive for viral
detection per high-powered field in areas where virus was detected. All samples were
assessed over the extent of the tumour cells. These areas were not formally controlled for
cell density but as the assessments were of tumour cells only it can be assumed the cell
density would be broadly similar. This is expressed as the average number ofpositive
cells per high-powered field (range 0-63) +/- standard error. These results are
summarised in figures 5.7 and 5.8. Both Student's t-test and Wilcoxan's rank sum tests
were used to compare the results between the wild-type and mutant p53 tumour samples.
5.4.1 In-situ hybridisation (ish) for detection of adenovirus in tumour
samples
ISH detected adenoviral DNA in 5 out of 10 samples with a mutation of p53 (50%) and
1 out of 4 with a wild-type p53 sequence (25%). The average density of virus found was
12.6+/-6 and 15.5+/-13 cells per high-powered field for mutant and wild-type tumour
respectively (figures quoted +/- SEM). Virus was detected in 3 samples at 24hrs; 2
samples at 72hrs and 1 sample at 14 days. The average density of virus was at 16 cells
per hpf at 24hrs; 9.2 at 72hrs and 12.4 at 14 days.
5.4.2 Immunohistochemistrv for detection of adenovirus in tumour
samples
Immunohistochemistry detected adenoviral hexon protein in 7 out of 10 samples with a
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mutation ofp53 (70%) and 1 out of 4 with a normal p53 sequence (25%). The average
density of virus found was 9.9+/-3.7 and 7.5+/-6 cells per hpf for mutant and wild-type
tumour respectively. Virus was detected in 4 samples at 24hrs; in 3 at 72hrs and in 1 at
14 days. The average density of virus was 9.6 at 24hrs; 10.2 at 72hrs and 6 at 14 days.
Virus was detected more often in p53 mut tumour samples using both ISH and IHC. A
similar density of virus in each group was found using both techniques, the result being
difficult to interpret as only one sample with a wild-type p53 sequence had virus
detected, but this had a high density of cells positive. The difference in both detection
rate and density between the mutant and wild-type samples is insufficient to reach
statistical significance using either Student's t-test or the Wilcoxan's rank sum tests.
Looking at the different timepoints it does appear that there is a trend for less virus to be
found at day 14 compared to the earlier timepoints, but this difference is not statistically
significant.
5.4.3 Detection of adeno-virus in saline injected tumour samples
ISH detected adenoviral DNA was detected in 2 out of 15 samples of saline injected
tumour (13.3%) and immunohistochemistry detected adenoviral hexon protein in 3 out
of 15 samples of saline injected tumour (20%). All of these had a mutation of p53. This
shows that less virus is detected in saline injected samples as compared to virus injected
tumours and this difference is statistically significant using the t-test and the Wilcoxan's
rank sum test (p=0.039 and p<0.01 respectively). There is some evidence of spread of
the virus from injected to non-injected areas but clearly this phenomenon is limited.
5.4.4 Detection of adenovirus in normal tissue samples
In the normal tissue biopsies ISH detected adenoviral DNA was detected in 2 out of 15
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samples (13.3%). The density of cells positive for viral DNA was 12.5+/-5.5 for the
tumour samples and 1.4+/-0.9 for the normal tissue samples. Statistical analysis using
the t-test and the Wilcoxan rank sum test showed this to be a significant difference
(p=0.03 and p<0.02 respectively). This demonstrates a significantly increased level of
viral survival and replication in tumour samples than in normal tissue when assessed by
ISH when looking at both frequency of any virus being detected and the density of virus
in areas where it was present.
Immunohistochemistry detected adenoviral hexon protein in 2 out of 15 samples
(13.3%). The density of cells positive for adenoviral hexon protein was 8.6+/-2.9 for the
tumour samples and 0.6+/-0.4 for the normal tissue samples. Statistical analysis using
the t-test and the Wilcoxan rank sum test showed this to be a significant difference
(p=0.009 and p<0.02 respectively). This demonstrates a significantly increased level of
viral survival and replication in tumour samples than in normal tissue as demonstrated
by presence of adenoviral hexon protein. Gene sequencing was not performed on the
normal tissue sample due to the relatively small volumes of tissue available, but
immunohistochemistry for p53 status on all the samples staining positive for viral
detection indicated the presence of abnormal p53 (see below).
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Table 5.4 - Overall results for ISH to detect adenoviral DNA - wild-type v's mut
p53
Sample No Tumour dll520 Tumour saline
type injected - density iniected density +/-
+/- SEM SEM
Mut p53 10 12.6+/-6 1.3+/-0.4
Wild-type 4 15.5+/-13 0
p53
Table 5.5 - Overall results for immunohistochemistry to detect adenoviral hexon













Table 5.6 - Overall results for d!1520 tumour v's normal tissue
Normal tissue viral Tumour tissue viral
density +/- SEM densitv +/- SEM
ISH 0.6+/-0.4 12.5+/-5.5
IHC 1.4+/-0.9 8.6+/-2.9
5.4.5 Overall viral detection
Combining the results of the ISH and IHC for hexon protein for the tumour samples it
was possible to detect the virus in 10 out of 15 cases altogether (67%). This includes 8
out of 10 positive with mutant p53 (80%) and 2 out of 4 with wild type p53 (50%) (one
sample was inadequate for gene sequencing). This compares to detection in 3 out of 15
normal tissue biopsies (20%). As described above the difference in detection between
normal tissue and tumour tissue is statistically significant when either ISH or IHC are
used. This clearly shows that the virus can exist preferentially in tumour tissue as
opposed to normal tissue from a similar tissue type i.e. oral mucosa.
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Figure 5.4 - examples of ISH for adenoviral DNA in a tumour sample
injected with d!1520 72 hours prior to resection (p53 mutant sample)
X10 magnification X20 magnification
X40 magnification (note evidence of cytopathic effect)
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Figure 5.5 - examples of immunohistochemistry for adenoviral hexon










Levels of apoptosis in the dll520-injected tumour samples were expressed as an average
of apoptotic cells per high-powered field +/- SEM. A base line assessment of apoptosis
was not obtained as consent for this additional biopsy was not covered within the ethical
approval obtained for the protocol. In the tumours, fields were selected at the interface
between invasive tumour and normal tissue. Malignant cells only were used for these
assessments within the tumour samples. A minimum of five fields was assessed per
tumour sample. In the normal biopsies apoptosis was assessed in the same manner with
fields chosen between the epidermis and deeper layers. The values were as follows:
Table 5.7 - Tunel stain to detect apoptosis
Tumour- Tumour- Normal
dl1520 saline +/- SEM
injected +/- injected
SEM +/- SEM
24hrs 4.6+/-1.1 1.8+/-0.2 6.1+/-2.2
72hrs 1.7+/-0.52 2.5+/-0.5 5.3+/-3
14 days 2.8+/-1.2 2.5+/-0.5 3.2+/-1.6
Alt 3+/-1.1 2.3+/-0.42 4.9+/-1.3
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Figure 5.6- apoptosis in a normal tissue biopsy
(X20 magnification) (X40 magnification)
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Figure 5.7 - appptosis in a d!1520 injected tumour tissue biopsy.
(X20 magnification)
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24hrs 72hrs 14 days
Time-point.
The graph demonstrates an increase in apoptosis in the normal, dl 1520 injected tissues as
compared to the dl 1520 or saline injected tumours at the 72 hr time-point. Comparing
the values for dll 520 injected tumours and the normal tissue at 24 hrs and 72 hrs this
difference is significant (p<0.01) (Wilcoxan's Rank sum test). This increased apoptosis
is lost by the 14-day time-point where there is no significant difference between the
normal tissues and the tumour tissues. There was no significant difference in apoptosis
between the dll520 injected and saline injected tumours. This suggests that the dll520
virus can lead to high levels of apoptosis in normal tissue.
This might be expected as when adenovirus inoculates into a normal cell, i.e. that with a
functional p53, the viral ElA protein activates p53 via a pathway involving the









cells as per the purported mechanism of action of the virus. Injecting dl 1520 into normal
tissue would therefore trigger an initial rise in cell apoptosis via this p53 pathway. This
would not lead to viral replication in such tissues as the apoptosis triggered in this way
prevents the virus replicating within these normal cells as the apoptosis effectively kills
the host cell before replication can take place [80, 134]. Levels of apoptosis were not
significantly different between viral and saline injected tumours. As most of the tumours
had a defective p53 function this would be expected, as the virus would not trigger high
levels of apoptosis in p53 deficient tissue.
When we look at tumour samples with wild type as opposed to mut p53 we find the
following results:
Table 5.8 - Tunel stain for apoptosis bv p53 sequence
Tumour type Tunel +/- SEM
Mutant (n=10) 3.42+/-2.84
Wild-type (n=4) 2.55+/-1.12
The level of apoptosis in the mut p53 samples is 3.42 as compared to 2.55 for the wild-
type samples. When either the t-test orWilcoxan rank sum tests are applied this
difference is not significant.
5.6 - P53 expression - immunohistochemistrv
The results of immunohistochemistry were determined using the scoring system based
on both the % of cells staining positive for p53 and the intensity of this staining as
previously described. This scoring system gives a maximum score of 6 and a minimum
score of 0. A high score for p53 would indicate the presence of an abnormal p53 protein,
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as the normal protein is unstable and not normally detected with immunohistochemical
staining techniques. It is accepted however that absent staining in the presence of
abnormal p53 can occur if there are truncations in both alleles meaning no p53 protein is
produced [163].
The results are shown in table 5.9 below. None of the samples with a wild-type gene
sequence stained positive for an abnormal p53 protein as would be expected. Of the
samples with a mutant p53 the dl 1520 injected samples scored an average of 3.2 +/-0.3
and the saline injected controls scored an average of 2.2 +/-0.5. This difference was not
statistically significant when the Wilcoxan rank sum test is used. Some samples with a
mutant p53 on gene sequencing did not stain positive for abnormal p53 protein using
immunohistochemistry. One explanation for this is that the genetic mutation involved
both alleles of the genome, making production of any p53 impossible. It is also possible
that if only very small quantities ofmutant p53 were produced they might not have been
detectable using immunohistochemistry [163], Most of the normal tissue biopsies did not
stain positive for abnormal p53 indicating that they did not have significant amounts of
abnormal p53. 5 of 13 biopsies did however stain positive for abnormal p53 with an
average score of 2.6 +/-0.3, indicating some defect in p53 production. This was the case
in both the normal tissue biopsies that stained positive for the presence of adenovirus.
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dll520 injected tumour mut
p53
3.2+/-0.3
dll520 injected tumour wt
p53
0
Saline injected tumour. 2.2+/-0.5
P53 abnormalities as detected by immunohistochemistry are apparently slightly higher in
tumour samples that in the normal tissue as would be expected. This difference was not
however significant when the Wilcoxan rank sum test was applied. Some staining for
p53 was detected in normal tissue biopsies, possibly indicating some abnormality of p53
function in these tissues.
Results were further analysed to see if there was a higher detection ofdll 520 in normal
tissue expressing p53 abnormalities compared to normal tissue samples that showed no
p53 expression.











P53 negative 0+/-0 0+/-0 0+/-0 0+/-0
P53 positive 1.14+/-0.35 3.5+/-0.3 0.25+/-0.2 0.125+/-0.1
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It can be seen that the samples staining positive for p53 in the normal tissue i.e. those
with abnormal p53 had apparently higher scores for both hexon adenoviral protein
expression and ISH for adenoviral DNA than those not staining positive for p53 i.e.
those with normal p53. The only result that showed a significant difference when the
Wilcoxan rank sum test was applied however was the ISH value for density (p=0.035).
5.7 - P21 expression - immunohistochemistrv
The results of p21 expression were expressed using the same format as p53 expression
above. Initially values were compared between tumour samples ofeither wild-type or
mutant p53 status. The results were as follows:
Table 5.11 - P21 expression in tissue samples correlated with p53 status
Tissue P21 expression +/- SEM
dl 1520 injected tumour wild-type 2.75+/-1.1
dl 1520 injected tumour mut 3.2+/-1.9
Saline injected tumour wild-type 3.25+/-1.1
Saline injected tumour mut 3.1+/-1.0
As the table shows there was no significant difference in p21 expression either between
the wild-type or mutant p53 groups or between the dl 1520 injected or saline injected
hemi-tumours. The results were further assessed to compare p21 expression at the
differing time points for all the different tissue types.
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Table 5.12-p21 expression in tissue samples at different time points
Tissue P21 expression +/- SEM
Tumour 24 hrs 2.4+/-1.4
Tumour 72 hrs 3.6+/-1.0
Tumour 14 days 3.2+/-1.1
Normal tissue 24 hrs 4.2+/-1.5
Normal tissue 72 hrs 4.8+/-1.3
These results show no significant difference between tumour samples or normal tissue
samples over the time course. It seems that p21 expression is higher in the normal tissue
samples than in tumour samples at all the time points assessed although his does not
reach statistical significance. P21 activity is associated with p53 activity as p21 is a
major down stream effector of p53. If the virus were triggering a greater apoptotic
response in normal tissue compared to tumour tissue this finding would be anticipated.
5.8 - Systemic immune response
Whole blood samples were taken at screening and at the day of surgery and assessed for
expression of various immune associated antigens as detailed in materials and methods.
An assessment was made of the ratio ofCD3/CD4positive to CD4 positive only cells
representing the ratio of lymphocytes to monocytes. Each subset of patients from the
three different time-points was analysed separately, giving five values in each sub-set.
The results are as follows:






24hrs 1.22 +/-0.16 0.5 +/-0.8
72hrs 2.13 +/-0.17 2.08 +/-0.37
14 days 2.21+/-0.3 1.63+/-0.17
This indicates that at the 24 hour time-point there was a significant drop in the ratio of
lymphocytes to monocytes, this being significant p<0.05 (Wilcoxon rank sum test). This
difference disappears at the later time-points.
An assessment was also made ofCD4 positive lymphocytes to CD8 positive
lymphocytes. The results are as follows:
Table 5.14 - ratio of CD4 +ve lymphocytes to CD8 +ve lymphocytes pre and post
viral injection
Screen Surgery




This indicates a drop in the ratio of 3+4 expressing lymphocytes to 3+8 expressing
lymphocytes at all time points although these values did not reach statistical significance.
These results were further analysed to see if these changes were due to an absolute drop
in the number of CD4 positive lymphocytes or a rise in the number of CD4+ve only cells
(monocytes) or CD4/CD8+ve cells. The following graph shows values of the various
groups expressed as a % of the total white cell count (WCC). This demonstrates that
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there was a fall in the number of CD3/CD4+ve cells and no change in the relative
number ofmonocytes or CD4/CD8+ve cells.
Table 5.15 - ratio of CD4 +ve lymphocytes to CD8 +ve lymphocytes as
compared to total number of monocytes pre and post viral injection
CD 4 +ve lymphocytes Monocytes (CD4 CD 8 +ve Ivmohocvtes (3+8
(3+4 +ve) % +/- SEM +vel % +/- SEM +ve) % +/- SEM
Screen 34.3+/-5.1 23.5+/-3.9 16.8+/-3
24hrs 16.4+/-4.2 36.2+/-5.6 18.4+/-5.3
72hrs 32.4+/-6.1 27.8+/-7.2 17.4+/-4.1
14days 32.8+/-6.0 27.4+/-5.5 14+/-2.8








The above results can be summarised as follows:
1. Direct intra-tumoural injection of dll520 is well tolerated in patients with primary intra-oral
SCC.
2. In this trial the use of the virus caused no significant side effects.
3. Direct injection of the virus into normal tissue specimens caused no evidence of tissue
damage or adverse events.
4. Following direct injection, the virus exists and replicates preferentially in tumour tissue as
opposed to normal tissue.
5. It is likely that the virus replicates preferentially in p53 mutant as opposed to p53 wild type
tumours, but this was not demonstrated to a level that would show statistical significance in this
trial.
6. Injection of the virus into normal tissue appears to stimulate increased apoptosis at the 24 hr
time-point. This is in keeping with the proposed mechanism of selective action of the virus i.e.
that once inoculated into cells with a functional p53 it would stimulate apoptosis.
7. Localised injection of the virus causes a transient, systemic drop in the CD4+ve lymphocyte
count which is manifest at the 24 hr post-injection timepoint.
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CHAPTER SIX -
DISCUSSION OF CLINICAL TRIAL RESULTS
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6.1 - Pre-operative injection of d!1520
Previous studies have demonstrated the successful use of the virus by direct injection in
lymph node metastases in SCC of the head and neck [137, 139]. These lesions were
essentially superficial in that the virus was administered trans-cutaneously. This study is
the first, in which intra-oral lesions were treated with this virus, which was administered
trans-mucosally within the oral cavity.
6.2 - Side effects and adverse events
Previous experience of the virus when administered by direct intra-tumoural injection
showed that side effects attributable to the virus such as pyrexia, headache and nausea
were recorded quite frequently [137, 139]. In this trial however no significant side
effects attributable to the virus were noted during this protocol. This could be explained
by the relatively low dose of adenovirus used in this study compared to previous trials
and the fact that only a single administration was used. The route of intra-tumoural
injection would not be expected to produce a significant systemic viraemia. The patients
in this series were also relatively fit and likely to have a more normal immune system
function as compared with the subjects in earlier studies who all had advanced, incurable
disease. Earlier studies where side effects were more frequent and severe involved high
doses and other routes of administration where viraemia was more likely e.g. intra¬
peritoneal infusion. This is further evidence that the intra-tumoural administration of an
El B deficient, replication competent adenovirus is safe in this group of patients. Other
adverse events that were recorded included free flap loss, respiratory failure and transient
ischaemic attack. In patients receiving major head and neck surgery these events would
be predicted and were not thought to be associated with the adenoviral injection.
Safety is a key issue with all new medicines but particularly with a field such as gene
therapy where potentially harmful viruses are used as carriers. D11520 is a replication
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competent virus meaning that any harmful effect of the virus might be propagated by
replication of the virus. There has in the past been one reported fatality of a patient on a
gene therapy clinical trial using a replication competent adenovirus where the death was
attributed at least in part to the virus being used as a carrier. This trial demonstrates that
the dl 1520 appears to have a good side effect profile with little risk of adverse events.
6.3 - Clinical effect
6.3.1 - Clinical effect - normal tissue
The apparent effect of the injection of virus into normal tissue was negligible in this
trial. This is in keeping with the theory of p53 selectivity for the virus as there would be
little or no dysfunction ofp53 within normal tissue. Some inflammation might be
expected after the injection of adenovirus but if there were little viral replication this
would be minimal and short lived, as was seen in this study. Any cell death would be
likely to be caused by apoptosis following viral injection in p53 competent tissue and
this would be an early, self-limiting event. This fact is of key importance in this study.
The main action that the virus is purported to have is based upon selective destruction of
tumour cells, in particular cells which have a p53 mutation.
6.3.2 - Clinical effect - tumour
In previous studies direct intra-tumoural injection of the virus into tumours caused
measurable tumour shrinkage often associated with tumour necrosis. No tumour
shrinkage was recorded in this series despite most of the tumours having p53 mutation
and there being evidence of viral replication in many samples. In such samples viral
replication leading to cytolysis would be expected with resultant tumour destruction. The
fact that this was not noted to a measurable degree is probably because the dose of
dl 1520 used was relatively low and only a single injection was used. In previous studies
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looking at the treatment of recurrent SCC of head and neck where clinical responses
were noted doses of up to 10n pfu were used and injections were repeated [139]. It is
possible that a higher dose or a multiple dosing schedule would have caused tumour
shrinkage in these primary tumour samples.
Previous laboratory and clinical studies have already demonstrated the ability of the
virus to cause shrinkage of tumours in both animal model and human studies and this
was not the intent of this study (see [75] for review). The most important point when
examining the results of this trial at a gross i.e. naked eye level is that the agent did not
cause damage to normal tissue despite a direct injection into this tissue. This means that
treatment protocols involving systemic or regional as opposed to local administration of
the agent might be possible.
6.4 - Histological analyses
6.4.1 - General findings
There was no evidence of gross tissue destruction due to the viral injection when overall
tumour size was considered. There was however microscopic evidence of some localised
cell lysis in tumour cells positive for adenoviral DNA. This effect was relatively minor
and it was not felt that it could be accurately quantified. All of the samples where this
was evident had a mutant p53 on gene sequencing. This would support the hypothesis
that the dll520 virus can cause selective tumour cell lysis in p53 negative tumour tissues
although the effect was localised and not sufficient in this trial to cause tumour
shrinkage. No evidence of lysis was found in the normal tissue biopsies or in tumour
biopsies with a wild type p53.
6.4.2 - DM520 distribution - immunohistochemistrv and in-situ
hybridisation
Immunohistochemistry for adenoviral hexon protein demonstrated evidence ofviral
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presence in 8 out of 15 samples of dl 1520 injected tumour. Of these seven had a
mutation of p53 and one had a normal p53 sequence. Adenoviral hexon protein was
detected in 3 samples of saline injected tumour. All of these had a mutation of p53. In
the normal tissue biopsies adenoviral hexon protein was detected in 2 samples.
Immunohistochemistry on both of these samples did indicate positive staining for p53
that might indicate a mutation leading to loss of function or of this protein [162, 163,
165],
In-situ hybridisation demonstrated evidence of adenoviral DNA in 6 samples of dl 1520-
injected tumour. Of these five had a mutation of p53 and one had a normal p53
sequence. Adenoviral DNA was detected in 2 samples of saline injected tumour. Both of
these had a mutation of p53 and none had a normal p53 sequence. In the normal tissue
biopsies adenoviral DNA was detected in two samples.
These results show that the dl 1520 virus is replication competent within human
squamous carcinoma even after a single injection of a low viral dose. We have
demonstrated a relatively high level of virus detection (11 out of 13 cases altogether
when the two detection modalities are combined) compared to earlier trials where a
larger dose of virus was used to treat recurrent tumours. In a phase I trial virus was only
detected in 4 out of 22 samples and in a phase II trial using dl 1520 and chemotherapy
virus was detected in 4 out of 10 cases [137, 139]. This could be due to the relatively
small tru-cut biopsies obtained from large, heterogeneous tumours in the earlier studies
leading to a sampling error rather than being due to increased levels of virus replication
in these primary tumours. This is compared to the analyses from this study where
sections of entire hemi-tumours were analysed.
There was little evidence of viral survival or replication in p53 wild-type tumours. Only
one out of four wild-type tumour showed a positive stain for hexon protein at the 14 day
time point and one out of four showed positive staining for adenoviral DNA using in-situ
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hybridisation at the 72 hr timepoint. In both cases the virus was only present in 2 high-
powered fields in each sample, indicating a relatively small amount of virus in each
example.
These findings suggest that the virus can exist preferentially in p53 negative tumour
tissue although it can survive in tumours with a normal p53 gene sequence. It was not
possible to demonstrate a statistically significant difference between the p53 wild-type
and mutant tumour samples however due probably to the small numbers involved. There
was however a statistically significant difference between all the tumour samples and the
normal tissue samples overall when all the timepoints for analysis were taken together.
The main thrust of the argument for the selective anti-tumour effect of dl 1520 is that the
specificity is due to p53 function of tissues. This has been demonstrated in several
studies looking at both cell line and xenograft models using the virus alone or in
combination with other agents. [1, 6, 7, 134]. It is therefore an important point to
determine whether the virus can exist and to what extent it can replicate within tissues of
each p53 status. D11520 has been specifically designed to be replication deficient in p53
competent tissues although this has been a matter ofmuch debate[5] (see below). Our
results indicate that the virus has a preference for p53 mut tumour tissue as opposed to
either wild-type tumour tissue or normal tissue. The selectivity is not absolute and we
did detect small amounts of virus in both p53 wild-type tumour and normal tissue.
There are several explanations as to why the virus can exist in p53 wild-type tumour
samples. The first is to acknowledge the gene sequencing technique used, as with all
such techniques, is not certain to pick up all the mutations present in any specific gene. It
is not impossible therefore that the two samples that showed evidence of viral replication
harboured mutations, which were not detected by the gene sequencing. Another
possibility is that even with a wild-type gene sequence for p53 the entire cycle ofp53
function could be disturbed by mutations in other important cell cycle regulator genes
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such as p21, pi 9 or pi 6 [9, 111, 166]. It is possible therefore that the function of p53 as
the key regulator of apoptosis following viral inoculation as a whole could be disrupted
by factors other than the p53 itself [25].
Another explanation is the ability of the dll520 virus to exist and even replicate within
p53 functional tissue. Several papers have demonstrated the ability of the virus to exist
and replicate within p53 competent tumour cells in both a tissue culture and tumour
xenograft model [1, 126]. According to the theory of the select action of the virus it
should be able to exist in p53 competent tissues and even cause limited cell death due to
apoptosis. It is salient that in the p53 wild-type samples where virus was detected there
was no evidence of cytolysis. If the virus could exist in tissue with a fully functional p53
protein it would be expected that in these wild-type tumours with viral presence there
would be an excess of apoptosis. This was not found in this study although the small
number of cases that involved tumour with wild-type p53 showing evidence of virus
makes any comparisons difficult.
The virus was usually confined to the injected hemi-tumour with little evidence of viral
spread to the saline injected control. Viral DNA was however detected in two saline
injected samples. This could either be due to viral spread throughout the tumour or to
inadvertent viral injection in the control tumour. The hemi-tumours were marked
carefully with tattooing of blue dye at the time of injection and great care was taken to
sample the correct areas once the tumours were resected and tissues were processed to
prevent this sampling error. The virus detected within the saline control samples was not
confined to the midline of the tumours and so it is likely that this effect is due to spread
of the virus. There was however little evidence of tumour spread with only two samples
showing this phenomenon. This implies that following a single injection the dll 520 is
capable of spread throughout a tumour but that this is a limited phenomenon.
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Figure 6.1 - Viral DNA in saline injected control sample
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There are many factors that could act to prevent the spread of virus throughout a tumour.
These include intra-tumoural pressure gradients, extracellular matrix molecules and
immune cells [167]. The fact that there was some evidence of viral spread into non-
injected tumour tissue after a single injection is encouraging and indicates that some
spread can take place. In total virus was detected in two saline injected samples by ISH
and in three saline injected samples by immunohistochemistry. All of the samples
demonstrated a mutant p53 sequence. Virus was not detected in any saline injected
samples with a wild-type p53 gene sequence. This would suggest that any distribution
through tumour not directly injected with the virus occurs preferentially in p53 null
tissue. Recent work involving dl 1520 in a human cell murine xenograft model has
previously demonstrated that distribution is related to p53 status in this model [132].
It was also noted that other factors concerning the method of injection could act to
increase distribution of virus, namely dividing the given dose of virus into several
injections and increasing the volume of carrier injected. Increasing the distribution of
virus in this way leads to increased anti-tumoural efficacy in this experimental model
[132]. As the volume of carrier as related to the volume of tumour mass was constant in
this trial, at 20% of the tumour volume, this factor should have been the same in all
cases.
6.4.3 - Detection of dl1520 in normal tissue
Three biopsies of normal tissue injected with dl 1520 demonstrated either presence of
hexon protein or adenoviral DNA. In two cases this was at the 24 hr timepoint and one
case at 72 hrs. There was no evidence of tissue destruction in these biopsies. All three of
these samples demonstrated positive immunohistochemical staining for p53 protein,
indicating that the protein was abnormal in some way. Gene sequencing was not
performed on the normal tissue biopsies but it is indicated by the positive staining that
there was probably some abnormality of function in these samples. It is not surprising
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that dl 1520 can survive for a limited period in normal tissues, as this would be predicted
by its proposed mechanism of action. The virus would be predicted to cause apoptosis in
infected normal tissue within a relatively early timescale and would not be expected to
replicate and cause cytolysis. Any tissue damage would be minor as little viral
replication or cytolysis would be expected. This is borne out by the fact that no gross
changes or ulceration was noted in the samples and there was no microscopic evidence
of tissue damage.
These results would refute recent suggestion that the dl 1520 virus can replicate
independently of the p53 status of host cells. It has always been known that the virus can
exist and replicate to a certain extent in p53 wild-type tissues of both tumour and normal
tissue although this is very restricted compared to levels of viral replication in p53 mut
tumour cell lines [1, 5]. It is also clear that the virus survives selectively in tumour tissue
as opposed to normal tissue following direct injection.
Recent publications have questioned this selectivity of action of the virus. Some workers
have suggested that the p53 selectivity of the virus is dose dependent, with p53
selectivity at low doses which is lost when higher doses of the virus are used [128]. This
loss of selectivity is proposed to be due to the fact that if sufficient adenovirus is present
in combination with sufficient cell numbers to be infected the virus is not dependent on
stimulating cells to enter S-phase. This means that the p53 status of cells is not crucial to
viral survival. Other workers have suggested that there are both p53 dependent and
independent factors required for the replication of the dl 1520 adenovirus [88]. This
paper confirmed that a functional p53 does restrict the level of dl 1520 replication but
that other factors were also involved. These other factors are thought to exist because the
E1B protein deficient in this virus is not just involved in inactivating the p53 protein but
also in the manufacture of late viral mRNA. The level of this dependence on E1B for the
manufacture ofmRNA seems to vary between host cell lines in a manner independent of
p53 status.
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Other factors which can play a part in determining the effectiveness of cytolytic viral
therapy in a given cell line include the infectivity and subsequent expression of early
viral proteins. This has recently been shown to vary between different human tumour
cell lines in a tissue culture model which again can explain why the effectiveness of the
virus can depend on factors other than p53 status of tissues [129].
Hall et al recently published results from tissue culture experiments suggesting that the
virus even required functional p53 to kill tumour cells [126]. This is in direct
contradiction to both the theoretical situation and the findings ofmost workers in this
field. It is noteworthy that these workers used only a tissue culture model and did not use
exactly matched cell lines i.e. cell lines identical except for p53 function. They also
analysed results at a relatively early stage when viral replication may not have been as
important as initial viral infection. As shown above there are many factors which could
potentially influence the ability of dll520 to replicate and cause cytolysis so the only
way to demonstrate p53 functional requirements accurately is to use matched cell lines.
Other authors have also described results indicating that the virus can replicate within
cell lines, both cancer and primary cultured strains, although confirming that this effect
is often p53 dependent in the degree of replication [88]. These findings are quite
different to those initially reported by Bischoff et al 1996 and Heise et al 1997. Both
these original papers reported evidence from multiple tissue culture and murine
xenograft experiments to suggest that the virus was selective for replication and cytolytic
effect in p53 mut tumour cell lines.
The conflicting evidence from these papers suggests that under certain circumstances the
virus can exist and to a greater or lesser extent replicate within p53 wild-type tumour cell
lines and some normal cell lines. As most of the results above are from tissue culture
experiments only they do not necessarily reflect the situation when the virus is used in a
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clinical setting. It is not clear of the significance of viral detection in normal and p53
competent tissue. So long as there is no evidence of harm to normal tissue the fact that a
small amount of virus can be detected in biopsies does not rule out the safety of the virus
as a treatment for tumours.
The goal of this form of gene therapy would be systemic delivery of virus rather than
intra-tumoural injection. This would allow microscopic, undetectable deposits of tumour
to be treated with the virus along with any clinically obvious disease. It has been
demonstrated that intra-venous viral delivery is feasible and causes tumour regression in
a murine xenograft model using a p53 mut human tumour cell line. If this were to be
repeated in humans the virus would have to be selective for tumour cells with little risk
of damage to normal tissue. Our study has demonstrated that even after a direct injection
of virus into normal tissue no damage to the tissue was demonstrated. The fact that virus
was detected in a small number of such tissue samples does not mean that the cytolytic
activity of the virus is not selective. We have demonstrated that any cytolysis does seem
to be selective for p53 mut tumour tissues. This would encourage the possibility of
dll520 being a possible agent for systemic gene therapy of human tumours.
6.4.4 - Apoptosis
Tunel staining was used to investigate the mechanism of cell death within injected
samples. The results indicated that apoptosis was occurring within both the saline
injected tumour samples and the viral injected tumour samples. In the dl 1520 injected
samples there was an initial high level of apoptosis at 24 hrs, which quickly tailed offby
72 hrs. The saline injected samples did not have this initial high level but this difference
was not statistically significant between the two. A relatively high level of apoptosis was
noted in the normal tissues at the 24 hr timepoint and this value was statistically
significantly higher that in the saline injected sample. This indicates that at 24 hrs the
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dl 1520 stimulate apoptosis in both normal tissue and tumour samples. In the normal
tissue this apoptosis persists until at least 72 hrs whereas in the tumour sample the
apoptosis level comes down by 72 hrs. If it had been possible to obtain baseline biopsies
from the normal tissue this would have given very useful information to indicate if these
differences were real or due to chance, but consent for these additional biopsies was not
obtained for this trial.
It has been previously noted that the dl 1520 virus can kill tumour cells via apoptosis in a
tissue culture model and that this effect is increased in p53 competent cells [136]. It is
also well recognised that intra-oral SCC can undergo apoptosis in response to
chemotherapeutic regimens [168]. D11520 is purported to destroy p53 null tumour cells
principally by direct cytolysis. P53 wild-type cells should respond to inoculation with
dl 1520 by undergoing apoptosis. In this study no difference in levels of apoptosis
between dl 1520 injected hemi-tumours or saline injected was noted when all time points
were assessed. If the 24hr delay samples were taken in isolation however there was an
increase in apoptosis between the virus and saline injected samples although this did not
reach significance.
This is in keeping with the previously noted fact that dll520 can stimulate some
apoptosis even in p53 mutant tumour cells. As none of the 24hr delay samples had a
wild-type p53 configuration it is impossible to say whether a wild-type sample would
have had higher levels ofapoptosis. This effect seems to be lost at later time-points with
no difference between the groups at 24hrs or 72 hrs. This could be explained if the virus
stimulated a burst of apoptosis in susceptible cells following inoculation. Following this
those cells susceptible to this cell death would die in a controlled fashion, limiting local
virus spread. This effect would be short lived.
There was also no significant difference in apoptosis levels between p53 mutant or wild
type tumours. As few wild-type tumours were assessed, and all of these at the later time-
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points, it is hard to draw any conclusions from this. In theory the virus should stimulate
relatively high levels of apoptosis in p53 wild-type tumours due to the action of the viral
E1A protein stimulating DNA synthesis which is a trigger to p53 mediate apoptosis
[119]. This effect would be expected soon after injection and as none of the samples
with wild-type sequence were from the 24hr group it may simply have been missed in
these samples as they were sampled after the effect had rescinded.
Increased apoptosis was noted in the normal tissue biopsies at all the time-points
assessed. It would be expected that injection of the virus into normal tissues with a
functional p53 dependent apoptotic pathway would stimulate apoptosis to a relatively
high level. As before the action of the ElA viral protein would lead to p53 mediated
apoptosis in these tissues. This effect would lead to a containment of the viral infection
with little viral replication and this was seen in this trial as by day 14 the level of
apoptosis had decreased.
The above findings are supportive of the concept that dll520 can induce high levels of
apoptosis in normal tissues. It also suggests that apoptosis in tumour tissues, including
those with mutant p53, can be stimulated. In the wild-type adenovirus the E1B protein
blocks apoptosis via the p53 pathway. It has also been suggested that E1B can also block
apoptosis mediated by the Bax protein. This protein is known to bind the ElB 19K
protein and it is thought that this is another mechanism by which an adenovirus can
prevent apoptosis of the host cell [119]. The Bax protein has been demonstrated to be
able to induce apoptosis independently of p53 and it is possible that in the p53 mut
tumours some apoptosis could have been induced via this pathway.
It is clear that just as p53 can lead to apoptosis via several different stimuli so apoptosis
can be triggered via other mechanisms that do not involve p53 [169]. It is known for
example that in oral carcinoma cells collected in India over expression of the heat shock
HSP70 protein acts to block apoptosis of tumour cells [118]. This could explain the fact
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that apoptosis was not noticeably higher in p53 wild-type tumours as compared to p53
mut tumours.
6.4.5 - Immunohistochemistry for p53/p21
Immunohistochemical staining for p53 demonstrated a good correlation between staining
and gene sequencing. The four wild-type tumours on gene sequencing all stained
negative for p53, indicating a normal p53 protein that, due to its short half-life, is not
normally detectable by immunohistochemistry. This indicates that the
immunohistochemical results correlated with the gene sequencing results. Of the tumour
samples with a mutant p53 on sequencing 8 out of 10 stained positive for p53.
There are several possible explanations for this difference between the two detection
methods. It is known that methods of tumour fixation can affect the stability ofp53
protein which could affect the p53 staining pattern [163]. It is also possible that tumour
harbouring a mutation causing both alleles of p53 to be lost would not produce any p53
or insufficient to be detected. It is also relevant that the area biopsied for Genechip
analysis was by necessity different from that assessed by immunohistochemistry, even
though the areas would have been close together. This may have affected the
immunohistochemistry pattern as compared to the p53 sequencing [165]. As noted in the
materials and methods section, the Genechip analysis cannot be considered 100%
accurate. Any of the above factors could have contributed to the discrepancy between
gene sequencing and immunohistochemistry for p53.
There was no significant difference in p53 detection between the dll 520 injected tumour
samples and the saline injected. This was true at all the timepoints assessed. This would
indicate that the injection ofdll 520 virus was not stimulating p53 protein to be
expressed in these tumours. This would be expected as those tumours with a mut p53,
which is dysfunctional, would not be expected to respond to the injection of adenovirus.
In the wild-type cases where p53 protein would have been stimulated none was detected,
124
as immunohistochemistry tends to detect only abnormal p53.
The normal tissue samples showed little staining with p53 as would be expected in non-
tumour tissue. 8 out of 15 samples did stain for p53 indicating a degree of abnormality of
the protein within these tissues. It is well known that smoking and drinking can lead to
overexpression of p53 in the mucosa adjacent to SCC of the head and neck [90, 91]. All
the mucosal biopsies of normal tissue were taken from grossly normal buccal mucosa
distinct from the tumours. All the patients sampled were known smokers. It is not
surprising therefore that some overexpression of p53 was noted in these samples. It is
likely that such overexpression is due to mutations in the p53 gene and therefore loss of
function of the p53 protein as has been demonstrated in other studies [170] [4]. It is
noteworthy that in the three samples of normal tissue where virus was detected there was
also staining for p53, indicating a possible loss of function of this protein. This would
help explain the survival of the dl 1520 virus within these normal tissue samples although
not all the samples staining positive for p53 had evidence of viral survival.
P21 expression was found in all samples both the tumour and normal tissue and in wild
type and mut p53 tumour samples. The level of p21 expression did not vary between the
dll520 and saline injected tumours indicating that p21 was not preferentially stimulated
by the addition of the adenovirus. P21 is thought to be one of the main downstream
effector of p53 and expression of p21 would be expected to correlate with the activity of
p53 within the cell. Overall this is in keeping with the immunohistochemical findings of
this project as there was no difference between expression ofp53 between dl 1520 and
saline injected tumour samples. What is more surprising is the fact that p21 expression
in p53 mutant tumour samples was the same as that for wild-type samples. It might have
been predicted that there would be less p21 expression in p53 mutant tumours, as there
was little or no functional p53 to stimulate the formation of p21.
P21 has however been shown to be induced by p53 independent pathways however and
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could be acting in this case independently of p53 [112]. P53 can also act independently
of p21 to cause apoptosis [25] and so it could be expected that p21 can function and be
expressed independently of p53.
In the normal tissue samples levels of p21 were relatively high at all time points
following injection of the virus. This correlates with the level of apoptosis in the
samples, which was high compared to that found in the tumour samples. This would be
in keeping with the theory of the dll 520 adenovirus causing apoptotic cell death in
normal tissue. It can be surmised that p21 is playing a part in this apoptotic cell death.
There was no significant difference between the different timepoints. This was unlike the
levels of apoptosis however, which seemed to decrease at the 14-day timepoint. We
cannot therefore be certain that p21 expression is increased in normal tissue samples
following viral injection but we have produced some evidence to support this hypothesis.
6.5 - Systemic immune response
FACS analysis of peripheral blood samples taken at screening and immediately prior to
surgery were analysed to look at the effect on the immune system of direct intra-
tumoural injection of the adenovirus. The main finding of this was that we have
demonstrated a fall in the ratio of lymphocytes to monocytes and also a fall in the ratio
ofCD4 positive lymphocytes to CD 8 positive lymphocytes. This finding has not
previously been documented following an intra-tumoural administration of viral therapy.
The changes in the peripheral blood picture are transient and disappear after 72 hrs. The
cause of these effects is not at present clear. Possible explanations might be
sequestration ofCD4 positive lymphocytes in to the injection sites or possibly the
destruction of the lymphocytes in the peripheral blood. This phenomenon has not been
previously described in the literature. It is unclear if this reaction was related solely to
the administration of adenovirus or was related to the effects of surgery. These findings
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would merit further investigation in any future clinical trial.
This drop in CD4+ve lymphocytes did not seem to affect the patients clinically in any
way. There was no evidence of increased risk ofwound or other infections and no
increase in complications compared to what would have been expected in the normal
course of events. The significance of this transient alteration in the peripheral blood count
remains to be determined.
127
CHAPTER SEVEN - CLONOGENIC ANALYSIS OF
CELL LINES A2780 AND A2780CP70 IN
COMBINATION WITH DL1520 AND
CHEMOTHERAPY AGENTS
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Clonogenic Analysis Of Cell Lines A2780 And A2780CP70 In Combination
With DM520 And Chemotherapy Agents
7.1 - Materials and methods
A tissue culture model was established to determine the effect of dll520 adenovirus in
combination with chemotherapeutic agents in two cells lines matched for p53 status. The
virus was incubated for either 24hrs or 72 hrs and the cells were then treated with
chemotherapeutic agents in varying concentrations. Clonogenic analysis was then carried
out to determine the number of viable colony forming cells left following this
treatment[20]. All assays were performed three times.
7.1.1 - Cell lines
Cell lines were derived from the ovarian carcinoma cell lines A2780 and A2780CP70.
These cell lines are matched for p53 status with A2780 having a wild-type p53 function
whereas A2780CP70 has been treated to have dysfunctional p53 [171] [19]. This p53
resistance has been established due to repeated treatments with the DNA damaging agent
cisplatin. The A2780 cell line is a cisplatin sensitive cell line. The A2780CP70 variant
has a greater monolayer growth rate and is 7.3 fold more resistant to cisplatin. This
resistance is related to dysfunction of the p53 tumour suppressor protein. These paired
cell lines are frequently used to investigate new potential drugs for use in drug resistant
tumours.
The cells were maintained in RPMI medium (anti-biotic free) supplemented with 10%
fetal calf serum. Cells were maintained in 5% C02 at 37°C and screening for
mycoplasma was undertaken monthly and any cell lines found to be positive were
discarded. No additional studies were made to determine the mechanism of cell death
within these assays.
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7.1.2 - Effect of incubation of dl1520 on A2780 and A2780CP70 in
combination with cisplatin
Cultures of both cell lines were trypsinised and suspended in medium. 5 X 105 cells were
added to 10mm petri dishes each containing 10ml ofmedium and the dishes were
incubated for 24 hrs at 37°C in 5% C02. The medium was aspirated and the cells in each
dish were washed with PBS, trypsinised using trypsin diluted 1:10 and resuspended in
medium and a cell count was made to determine the approximate number of cells per
dish. The virus was supplied in a concentrated form with the concentration expressed a
number ofplaque forming units (PFU) per ml stated, which was determined by plaque
assay using HeLa cells as previously described [5], Medium was aspirated from all
dishes and the cell monolayers were treated with either 500 pi PBS, 10 PFU/ cell dl 1520
in 500pl PBS or 50 PFU/ cell dl 1520 in 500pl PBS. The plates were incubated at 37°C
in 5% C02 for 90 minutes with regular mixing of the PBS every 15 minutes.
Non-absorbed virus was aspirated from each plate and 10 ml medium was added to each.
The plates were then incubated at 37°C in 5% C02 for either 24 hrs or 72 hrs. Medium
was then aspirated from each plate and replaced with cisplatin diluted in 10ml medium
at various concentrations. For A2780 concentrations of 0 pM, 1 pM, 5pM, lOpM and 20
pM were used and for A2780CP70 concentrations of 0 pM, 10 pM, 20pM, 40pM and
80 pM were used. This higher dose was used, as the A2780CP70 is known to be
relatively resistant to the action of cisplatin. Plates were incubated for one hour at 37°C
in 5% C02. Medium was again aspirated and the cell monolayers washed in PBS. The
cells were then trypsinised and counted. For each variable of virus concentration and
cisplatin concentration 103 cells were added to 10 ml medium in a 90 mm petri dish in
multiples of five for each value. Cells were incubated at 37°C in 5% C02 for 11 days to
allow colony formation. At this time colonies were washed in PBS, fixed in methanol
and stained for ten minutes with crystal violet. Colonies were then counted using the
colony counter and results expressed as a percentage of surviving fractions compared to
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the control i.e. no virus and no cisplatin.
7.1.3 - Effect of incubation of d!1520 on A2780 and A2780CP70 in
combination with topotecan
Cultures of both cell lines were trypsinised and suspended in medium. 5 X 105 cells were
added to 10mm petri dishes each containing 10ml medium. The plates were incubated
for 24 hrs at 37°C in 5% C02. The medium was aspirated and the cells in each dish were
washed, trypsinised and resuspended in medium. A cell count was made to determine the
approximate number of cells per dish. Medium was aspirated from all dishes and the cell
monolayers were treated with either 500 pi PBS, 10 PFU/ cell dl 1520 in 500pl PBS or
50 PFU/ cell dll520 in 500pl PBS. The plates were incubated at 37°C in 5% C02 for 90
minutes with regular mixing of the PBS every 15 minutes.
Excess virus was aspirated from each plate and the monolayers recovered with 10 ml
medium. The plates were then incubated at 37°C in 5% C02 for either 24 hrs or 72 hrs.
Medium was then aspirated from each plate and replaced with topotecan at various
concentrations in 10 ml medium. For both cell lines concentrations ofOnM, 50nM,
lOOnM, 200nM and 40nM were used. Plates were incubated for four hours at 37°C in
5% C02. Medium was again aspirated and the cell monolayers washed in PBS. The cells
were then trypsinised and counted. For each variable of virus concentration and cisplatin
concentration 103 cells were added to 10 ml medium in a 90 mm petri dish in multiples
of five for each value.
Cells were incubated at 37°C in 5% C02 for 11 days to allow colony formation. At this
time the colonies were washed in PBS, fixed in methanol and stained for ten minutes
with ciystal violet. Colonies were then counted using the colony counter and results




7.2.1 - Clonoqenic analysis of the action of d 11520 in combination with
cisplatin and topotecan
Two cell lines matched for p53 status, A2780 (wild-type p53) and A2780 CP70 (mutant
p53 ) were used to determine the effect of standard chemotherapeutic agents in
combination with dl 1520 [171]. The experiments were conducted following different
incubation times with the virus. Cells were incubated with the dl 1520 virus at
concentrations of 0, 10 or 50 pfu per cell for either 24 or 72hrs. These time-points were
used as viral replication would be near maximal after 72 hrs so at this time point effects
due to replication would be most evident [79]. At 24 hrs any effect due to apoptosis
alone would be more likely to be apparent as apoptosis is typically triggered by this time
following adenoviral inoculation [9]. Following the incubation period the cells were
treated with various concentrations of the chemotherapeutic agent under investigation for
a given time, one hour in the case of cisplatin and four hours in the case of topotecan.
Following treatment with the dll520 virus the cells were plated out for a clonogenic
analysis to determine the number of colony forming units that survived the treatment.
7.2.2 - Effect of DM 520 alone with A2780 and A2780CP70
It was found that the dll 520 virus has the capacity to kill cancer cells from both cell
lines tested i.e. with wild type or dysfunctional p53 in the absence of any chemotherapy
agent. The level of cell kill increased with higher inoculation ofdll 520 in the absence of
other agents. After 24hr virus exposure the % colony survival dropped from 67% at 10
pfu/ cell to 62% at 50 pfu/ cell for the A2780 and from 94% at 10 pfu/ cell to 66% at 50
pfu/ cell for the A2780CP70. At the 24 hr time-point therefore there is no increase in cell
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death in the A2780CP70 cells as compared to the A2780. In fact the opposite is
demonstrated, with less cell death in the A2780CP70 with the higher dose of virus at 24
hrs. At this point apoptosis rather than cytolysis would be the predominant mode of cell
death caused by the virus and so these findings are not unexpected.
After 72 hr exposure the % cell survival was 70% at 10 pfu/ cell and 70% at 50 pfu/ cell
for the A2780 and from 28% at 10 pfu/ cell to 12% at 50 pfu/ cell for the A2780CP70
See fig 3.1 and 3.2). It is clear therefore that in the p53 mutant A2780CP70 cells there is
a substantial increase in cell death following a longer incubation with the virus. At the
72 hr timepoint cytolysis, following viral replication, would be the main mechanism of
cell and so a cell line permissive for viral replication would demonstrate increased
susceptibility to death caused by the virus.
7.3.1 - Effect of the addition of cisplatin with d!1520 to A2780 and
A2780CP70 cell lines
The effect on cell death caused by the virus is enhanced by the addition of cisplatin in a
dose dependant manner in both cell lines as shown below. As would be expected a
higher dose of cisplatin is required in the A2780CP70 as opposed to the A2780 to obtain
a similar level of cell kill, due to the lack of functional p53 causing resistance to cisplatin
in the A2780CP70 cells.
Adding cisplatin alone to the A2780 cell line causes colony survival to drop from 78%
withlpM cisplatin to 10% with 20pM cisplatin. With the addition of 1 Opfu/ cell of
dll520 with 24 hr incubation with the virus the survival drops to 52% and 7 %
respectively for lpM and 20 pM (see fig 3.3). The addition of 50pfu/ cell of dl 1520 with
24 hrs incubation causes the colony survival to drop to 47% and 6 % respectively for
IpM and 20 pM cisplatin. The combination of 72hr incubation with dl 1520 along with
cisplatin shows that with the addition of lOpfu/ cell ofdl 1520, colony survival drops to
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70% with 1 pM cisplatin and to 4% with 20pM of cisplatin. When the viral concentration
is increased to 50 pfu/cell the values for colony survival are 70% for luM cisplatin and
2% for 20pM cisplatin respectively.
In the A2780 CP70 cell line, adding cisplatin alone causes colony survival to drop from
96% with20pM cisplatin to 29% with 80pM cisplatin. As noted above a larger
concentration of cisplatin is required with this cell line to achieve a similar colony
survival as compared to the A2780 cell line. Incubation for 24 hrs with lOpfu/cell dl 1520
causes the cell survival to drop to 83% with 20pM cisplatin and 16% with 80pM
cisplatin. Incubation for 24 hrs with 50pfu/cell dll520 causes the cell survival to drop to
48% with 20pM cisplatin and 9% with 80pM cisplatin.
Incubation of the A2780CP70 cell line for 72 hrs causes a different level of cell death.
With lOpfu/cell dll520 causes the cell survival to drop to 12% with 20pM cisplatin and
1% with 80pM cisplatin. Incubation for 72 hrs with 50pfu/cell dl 1520 causes the cell
survival to drop to 6% with 20pM cisplatin and 0.5% with 80pM cisplatin.
It can be seen from the above results that increasing the length of exposure to dll 520 has
a different effect on each cell line. After 24 hr exposure to 50 pfu of the virus the
difference in effect ofdll 520 between the two matched cell lines is minimal with a 62%
survival with the A2780 and a 55% survival with the A2780CP70. After 72hr exposure
however there was a marked increase in cell killing activity in the p53 null A2780CP70
compared to the wild-type A2780 with a 70% survival with the A2780 and a 12%
survival with the A2780CP70.
A similar pattern was found using lOpfu of virus with survival of 67% at 24hrs with
A2780 and 94% with A278CP70 but 70% as opposed to 28% following 72hrs viral
exposure. It would appear that the differential in viral killing between cell lines of
varying p53 status is time dependent. This is in keeping with the proposed mechanism of
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action of dl520, as the differential activity would rely on viral replication to disseminate
further virus following cytolysis. At 24 hrs however there would not have been sufficient
time for this effect to be manifest.
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Figure 7.1 - Effect of incubation of A2780 cells with dl1520 at various
concentrations for 24 or 72 hours
Figure 7.2 - Effect of incubation of A2780CP70 cells with d!1520 at various




Figure 7. 3 - The effect of a combination of cisplatin + 24hr exposure to
dl1520 in the A2780 cell line
Figure 7. 4 - The effect of a combination of cisplatin + 72hr exposure to
d!1520 in the A2780 cell line
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Figure 7. 5 - The effect of a combination of cispiatin + 24hr exposure to
d!1520 in the A2780CP70 cell line
Figure 7. 6 - The effect of a combination of cispiatin + 72hr exposure to






Table 7.1 Clonoqenic survival of A2780 cells following 24 hr exposure to d!1520
and exposure to cisplatin as shown. Values expressed as % of control value
[cisplatin] Control +/- 10pfu +/- 50pfu +/-
uM SEM SEM SEM
0 100+/-6 67+1-3 62+1-5
1 78+1-5 52+1-2 47+1-5
5 42+1-2 25+/-1 30+/-1
10 28+1-2 18+/-3 18+/-3
20 10+/-2 7+/-1 6+1-2
Table 7.2 Clonoqenic survival of A2780 cells following 72 hr exposure to d!1520
and exposure to cisplatin as shown. Values expressed as % of control value
[cisplatin] uM Control +/- 10pfu +/-SEM 50pfu +/-
SEM SEM
0 100+/-5 70+/-5 70+/-4
1 78+1-6 54+1-2 52+1-2
5 46+1-4 30+/-2 22+1-2
10 26+1-4 10+/-2 10+/-1
20 9+/-1 4+/-1 2+/-1
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Table 7.3 - Clonoqenic survival of A2780CP70 cells following 24 hr exposure to
dl1520 and exposure to cisplatin as shown. Values expressed as % of control
value
[cisplatin] uM Control +/-
SEM
10pfu +/-SEM 50pfu +/-
SEM
0 100+/-5 94+/-10 66+/-7
20 96+/-11 83+/-9 48+/-5
40 92+/-9 68+/-8 34+/-6
60 35+/-8 23+1-5 13+/-2
80 29+/-4 16+/-5 9+/-1
Table 7.4 Clonoqenic survival of A2780CP70 cells following 72 hr exposure to
d!1520 and exposure to cisplatin as shown. Values expressed as % of control
value
[cisplatin] uM Control +/-
SEM
10pfu +/-SEM 50pfu +/-
SEM
0 100+/-5 28+1-2 12+/-3
20 94+/-1 12+/-2 6+/-3
40 57+1-5 5+/-1 3+/-1
60 19+/-1 2+/-1 1+/-1
80 12+/-0 1+/-1 0.5+/-1
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7.4 - Effect of the addition of topotecan and dl1520 to the cell lines A2780
and A2780CP70
The above experiment was repeated using topotecan as the chemotherapeutic agent with
concentrations of 0, 50, 100, 200 and 400nM of the drug in solution. Results again
showed that dll 520 has the capacity to kill cancer cells from both cell lines i.e. with wild
type or mutant p53. These experiments gave a pattern of results similar to the previous
experiment using a combination ofdll520 virus plus cisplatin. A higher level of cell kill
was demonstrated with increasing inoculation with dll 520 in the absence of topotecan.
The level of cell kill increased from a % colony survival of 77% at 10 pfu/ cell to 70% at
50 pfu/ cell for the A2780 and from 79% at 10 pfu/ cell to 45% at 50 pfu/ cell for the
A2780CP70 after 24hr virus exposure. After 72 hr exposure the % cell survival was 78%
at 10 pfu/ cell to 48% at 50 pfu/ cell for the A2780 and from 43% at 10 pfu/ cell to 22%
at 50 pfu/ cell for the A2780CP70. This effect is enhanced by the addition of topotecan
in a dose dependant manner in both cell lines as shown in figure 7.1.
Increasing the length of exposure to dll 520 has a different effect on each cell line. After
24 hr exposure to 50pfu of the virus the difference in effect ofdll 520 between the two
matched cell lines is minimal with a % survival of 70% with the A2780 and a % survival
of 45% with the A2780CP70. After 72hr exposure however there was a marked increase
in cell killing activity in the p53 null A2780CP70 compared to the wild-type A2780 with
a % survival of 48% with the A2780 and a % survival of 22% with the A2780CP70. A
similar pattern was found using lOpfu of virus with survival of 77% at 24hrs with A2780
and 79% with A278CP70 but 78% as opposed to 43% following 72hrs viral exposure.
These patterns were repeated using various concentrations of topotecan as shown by the
following graphs.
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Figure 7.7 - The effect of a combination of topotecan + 24hr exposure to
d!1520 in the A2780 cell line
120 n
[Topotecan]nM
Figure 7.8 - The effect of a combination of topotecan + 72hr exposure to
dl1520 in the A2780 cell line
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Figure 7.9 - The effect of a combination of topotecan + 24hr exposure to





Figure 7.10 - The effect of a combination of topotecan 72hr exposure to
dl1520 in the A2780CP70 celt line






Table 7.5 - Clonogenic survival of A2780 cells following 24 hr exposure to






10pfu +/- SEM 50pfu +/-
SEM
0 100+/-5 77+1-5 70+/-6
50 71+/-5 73+1-6 53+1-5
100 68+/-6 62+1-3 45+1-5
200 67+/-3 49+1-6 43+1-6
400 60+/-1 53+1-6 32+1-6
Table 7.6 - Clonoqenic survival of A2780 cells following 72 hr exposure to










0 100+/-5 78+1-4 48+/-5
50 58+/-4 38+1-4 29+1-3
100 55+1-5 37+1-4 26+1-4
200 37+1-4 36+1-3 22+1-3
400 29+1-5 34+1-3 ^ 6+1-4
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Table 7.7 Clonoqenic survival of A2780CP70 cells following 24 hr exposure








0 100+/-5 79+1-5 45+1-3
50 67+/-5 67+1-3 30+1-2
100 57+1-5 47+1-3 26+1-3
200 53+1-4 45+1-2 23+/-1
400 46+1-2 37+/-1 23+1-2
Table 7.8 - Clonogenic survival of A2780CP70 cells following 72 hr exposure





0 100+/-5 43+/-7 22+1-2
50 62+1-5 30+/-3 ^ 5+1-2
100 74+1-6 27+1-6 12+/-1
200 67+1-6 27+1-6 10+/-1
400 63+1-6 26+1-5 10+/-1
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Exposing cell lines matched for p53 function to topotecan and the dll 520 virus, we
demonstrate a variable cytopathic effect at different time points. Following 24hr
exposure to the virus there is no significant difference between the level of cell kill in
A2780 or 2780CP70 cells. After 72 hr virus exposure however there is a significant
increase in cell kill in the p53 mutant A2780CP70 cell line. This would be expected, as
the A2780CP70 cell line is permissive for viral replication whereas the A2780 cell line,
with wild-type p53, should not be. This differential would not be apparent after 24hr
virus exposure, as cell death at this point would be expected to be predominantly due to
apoptosis. Following viral replication at 72hrs timepoint however the difference in viral
replication would be manifest, as a higher cell kill in the A2780CP70 cell line.
Taken together the above experiments indicate that the dll520 virus can act in an
additive fashion with other chemotherapeutic agents at all time points assessed. There
was no evidence of antagonism between the agents. After 24 hour exposure to dll 520
there is little difference between the wild-type and p53 null cell lines in terms of their
response to the virus. At the later time period of 72 hrs however there was an enormous
increase in cell killing in the p53 deficient A2780CP70 cell line. This is probably due to
the differential between the p53 wild-type and null being caused by viral replication. At
72 hrs viral replication would be expected to be at a high level whereas at 24 hrs little
replication would be evident. As the differential action of dll 520 is due to replication
inhibition in p53 wild-type cells this would fit the expected pattern for this virus.
7.5 - Discussion - clonoqenic analysis of dl1520 plus cisplatin and
topotecan
Cisplatin is a chemotherapeutic drug thought to act by covalently binding to DNA
disrupting DNA function and causing cell death in a p53 dependent manner [19, 172].
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Topotecan is a topoisomerase I inhibitor that causes cell death in a p53 independent
manner [20]. Both of these agents are in common clinical use in oncological practice.
We wished to determine if the action of an agent such as dl 1520 interacts with such
chemotherapeutic compounds in any way, either as an additive or antagonistic way. It is
possible that the virus might be used in combination with such agents in a clinical
setting.
Combining 24 hrs incubation with dl 1520 with a one hour exposure to cisplatin showed
similar results in both p53 positive and negative cell lines. In both cases the virus alone
caused significant reduction in clonogenic survival and this effect increased with the
addition of cisplatin at increasing concentrations. Addition of cisplatin caused an
additive effective in both cell lines with no significant difference between the p53
functional or null cell lines. A higher dose of cisplatin was required to give an equivalent
level of cell kill in the A2780CP70 as opposed to the A2780 as the p53 null cell line is
relatively resistant to this agent.
After 72 hr exposure to the virus however there was a dramatic difference between the
two cell lines with a greater cell kill in the p53 null cell line. A similar pattern was found
when virus was combined with a 4hr exposure to topotecan with no significant
difference between the two cell lines at 24hrs virus exposure. The longer exposure in the
A2780CP70 cell line led to a significant reduction in cell survival both with and without
the addition of chemotherapeutic agents.
The most obvious explanation for this is a difference in viral replication. After 24hrs
exposure the dl 1520 virus would be expected to inoculate both p53 functional and
mutant cell lines. It is accepted that the virus can trigger cell death by apoptosis in both
p53 positive and negative cell lines [136] and that this effect can be greater in p53
competent cell lines. This effect is due to a p53 mediated action triggered by the
adenoviral ElA protein following viral inoculation into cells and is a protective
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mechanism designed to prevent viral replication causing widespread tissue damage
[119]. This mechanism of apoptotic cell death could occur in an additive fashion with
both the chemotherapeutic agents tested and would be expected to occur soon after viral
inoculation in susceptible cells.
After 72hrs virus incubation however the effect of viral replication would be more
important. Adenovirus causes most of its cytopathic effect during the late phase of the
viral replication cycle after 48 hrs [79]. Following this cytopathic effect virus is shed and
viral integration into neighbouring cells can occur. Where replication of virus is
prevalent therefore a greater cytopathic effect is seen. This occurs following the longer
viral infection in the p53 deficient cell line. In the p53 competent cell line however little
viral replication would be expected as in theory the virus would trigger p53-mediated
apoptosis before replication could take place. This would abrogate viral replication
diminishing the cytopathic effect and also reducing viral spill into the culture medium
releasing less virus for subsequent inoculation of cells. In the p53 null cell line this
apoptosis would be significantly reduced, meaning viral replication and ultimately
increased cytolysis could happen.
These results confirm the p53 selectivity of viral replication with increased cell death in
p53 null cells following a 72hr viral incubation. It is clear however that the virus also
causes increased cell death in p53 competent tumour cells when combined with
chemotherapy and one can hypothesise that this effect is mediated by apoptotic cell
death. Initial cell death is therefore to be expected in p53 competent cell lines in the early
stages following viral inoculation but there should not be a large increase in this effect
following a longer inoculation. One weakness of the above study is that no investigations
of the mechanism of cell death were performed. This could be an area of future research
as the nature of cell death in these two cell lines is of significant interest.
The virus has been shown previously to act in an additive fashion to decrease tumour
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size with standard chemotherapeutic agents in a murine xenograft model (cisplatin and
5-FU) when administered intra-tumourally or intravenously [1]. Other workers have also
demonstrated an additive effect with dll520 and chemotherapy in a tissue culture model
using primary lung cancer cell lines [7]. Our results again demonstrate that the dl 1520
adenovirus can act in an additive fashion with other commonly used chemotherapeutic
agents. We demonstrate little additive benefit of cisplatin when used with A2780CP70,
the p53 deficient cell line. Using either lOpfu or 50 pfu of virus demonstrates high levels
of cell killing even without the addition of cisplatin. To demonstrate synergy in this
setting it may have been beneficial to use lower doses of virus. It is also important to
bear in mind that most head and neck SCC samples show heterogenicity ofp53
expression, in contrast to the cell lines investigated here [173] [174]. In a clinical setting
therefore any treatment regime would probably have to target both p53 wild-type and
mutant cells.
It is important that dl 1520 shows no evidence of antagonism to standard chemotherapy
agents. In the clinical setting it is likely that a viral therapy such as dll520 would be used
in combination with other treatment modalities such as chemotherapy This was the case
in the recent successful phase II trial of dl 1520 in combination with chemotherapy in
head and neck cancer [139].
It is logical to combine a gene therapy treatment that is selective for p53 negative tissue
with another treatment modality that can target tumour cells with functional p53. This
can give a combined therapy modality that can destroy cancer cells with both functional
and non-functional p53. It is well recognised that the loss ofp53 function contributes to
chemo- and radio- resistance in many tumours which initially respond to these therapies
but become refractory to treatment [19]. A treatment that specifically targets such
resistant tumour cell lines and can be used alongside conventional treatments, which
target p53 functional cells, is therefore desirable. The above experiments indicate that
dl!520 could be used in such a manner. There is a potential area of concern in that the
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dl 1520 appears to act in an additive fashion with both p53 functional and dysfunctional
cell lines. In theory this could increase the risk of damage to non-tumour tissues in
clinical trials, especially if systemic delivery was used. To date however, no such clinical
effect has been noted[92].
7.6 - Summary
These in-vitro studies therefore demonstrate the following:
1. D11520 can act to kill cancer cells with both functional and dysfunctional p53 in an
additive fashion when combined with chemotherapy.
2. The effect of dll 520 differs with the p53 status of cells in a time dependent fashion.
For the differential effect of the virus between p53 wild-type or mutant cells to manifest,
a sufficient time interval must elapse to allow for viral replication. The difference in
effect is probably due to differential viral replication, which is maximal at about 72 hrs
following inoculation.
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CHAPTER EIGHT - A SINGLE INJECTION OF
dl1520 INTO MURINE XENOGRAFTS
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8.1 - Materials and methods
8.1.1 - Hexon stain for adenoviral protein expression
Paraffin sections were derived from tumour xenografts, grown as detailed below. The
tumours were preserved in formalin and processed in a standard fashion prior to wax
embedding and sectioning. The sections were then dewaxed in three changes of xylene
for 5 minutes each and rehydrated through a series of 100%, 90% and 70% ethanol and
distilled water. Immersing the slides in 3% hydrogen peroxide in methanol for 45
minutes quenched endogenous peroxidase activity and the slides were rinsed in two
changes of PBS. The sections were then treated with protease (Pronase, Meridian
diagnostics 1.7mg/ ml in PBS) for 20 minutes in a humidified chamber at 35° C and the
slides were rinsed in two changes of PBS. Casein solution was used to block non¬
specific (Power Block casein solution, Biogenex diluted 1:10 in PBS).
The mouse primary anti-adenovirus monoclonal antibody Iglk isotype (Chemicon) was
used at a dilution of 1:1000 and 100 pi was added to the section and a coverslip added.
This was incubated for 45 mins in a humidified chamber at 35°C and slides were rinsed
in two changes ofPBS.
Subsequent antibodies were provided from the Biogenex Super Sensitive
Immunodetection System, Biogenex. 100 pi of a biotinylated secondary antibody was
added to each section and incubated for 20 mins at room temperature and slides were
rinsed in two changes of PBS. Streptavidin-horseradish peroxidase conjugate (100 pi)
was added to each section and incubated for 20 mins at room temperature and slides
were rinsed in two changes of PBS. DAB was used as a chromagen with 100 pi added to
each section for 8 mins. Slides were then rinsed in distilled water, counter-stained in
Mayer's hematoxylin for 2 mins and dipped in Ammonia water for 10 seconds. Sections
were dehydrated through 70%, 90% and 100% alcohol prior to being immersed in three
changes of xylene. Sections were mounted using permount. Murine xenograft sections
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known to harbour adenovirus were used as positive controls and pbs injected samples as
negative controls. All analyses were performed three times. Counts of cell infectivity
were made in a minimum of five high-powered fields for each section.
8.1.2 - Protocol for growth of murine xenografts
8.1.2.1 - Animals
Six week old athymic MFU nude mice were supplied and maintained according to
standard protocols.
8.1.2.2 - Raising of xenografts
Cell lines A2780 and A2780CP70 were cultured as described previously. Cells were
trypsinised and counted and centrifuged at 1500 rpm for 5 minutes to form a cell pellet.
The pellet was resuspended in PBS. 107 cells in lOOul of PBS were injected
subcutaneously at two sites per mouse. Each experiment was performed with two
cohorts of subjects.
8.1.3 - Preparation of dl1520 adenovirus
D11520 is formulated as sterile viral solutions in TRIS buffer (10 mM TRIS pH 7.4, 1
mM MgCl2, 150 mM NaCl, 10% glycerol). The product is supplied frozen in single-use
vials and contains no preservative. Virus was thawed in a biological safety cabinet and
diluted in PBS to give a concentration of 108 pfu in lOOpl of solution.
8.1.4 - A single intra-tumoural injection of dl1520 in A2780 and A2780CP70
8.1.4.1 - Injection of d!1520 adenovirus
Once palpable tumours were established, at about day five, tumours were injected with
either:
1. lOOul PBS.
2. 108 plaque forming units (pfu) dll 520 in lOOul PBS.
Injections were made by inserting a 23-gauge needle into each quadrant of the tumour
and infiltrating virus along the tract formed as the needle was withdrawn. Four needle
tracts were used for each tumour and 30 tumours were grown for each group. Tumours
were harvested at 24hrs, 72 hrs or 14 days determined by the maximal accepted size of
the xenografts. Tumours were fixed in 4% phosphate buffered formalin.
8.2 - Results
The tumours were harvested at three timepoints following virus injection - 24hrs, 72hrs
and 14 days. These three time-points were chosen to allow for the effects of viral
replication, which would be expected to be maximal at 72hrs and to tail off after this
time. Following tumour harvest and processing, histological specimens from the
xenografts were assessed for the presence of adenoviral hexon protein using
immunohistochemistry. A comparison was then made of the capacity of the virus to exist
and replicate in tumours identical except for their p53 status.
It became apparent during analysis that the virus tends to collect in cells located at the
interface between the necrotic tumour centre and the interstitium as has been previously
demonstrated (Fig 4.1). The amount of cells in which virus was detected at this interface
area was therefore used to assess viral presence in this experimental model. Assessments
were made of:
1. The % of cells staining positive for adenoviral hexon protein within each high
powered field at the interface area. This value gave an estimate of the density of virally
infected cells.
2. The % of high-powered fields at the interface containing any cells staining positive for
adenoviral hexon protein. This value gave an estimate of the distribution of virally
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infected cells in the area permissive for viral replication.
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Figure 8.1 - positive staining for adenoviral hexon protein. Black arrow
point to positive (dark brown) cells
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The % of cells staining positive for adenoviral hexon protein at the interface between
necrotic tumour centre and tumour interstitium was assessed. This assessment was made
by looking at each high-powered field that contained any cells staining positive for
adenovirus. The % ofpositive cells out of each high-powered field was calculated after
an assessment of at least four fields per histology slide, with values expressed +/- SEM.
This gave values of 18+/-4.9 % for A2780CP70 and 0 % for A2780 at 24hrs; 51.2+/-8.5
% for A2780CP70 and 3.3+/-0.7 %for A2780 at 72hrs and 32.3+/-10.8 % for
A2780CP70 and 2+/-0.6 % for A2780 at day 14. These differences were significant
p<0.05 at 24hrs; p at <0.05 at 72hrs and p <0.05 at day 14 when analyzed with Student's
t-test (see fig 8.2).
The % of high-powered fields containing any cells staining positive for adenoviral hexon
protein at the interface between necrotic tumour centre and tumour interstitium was
assessed. The total number of high-powered fields surrounding the necrotic centre of
each tumour was counted and then the % of these containing cells staining positive for
adenovirus was calculated.
This gave values of 20+/-1 % for A2780CP70 and 0 % for A2780 at 24hrs; 56.7+/-6.2%
for A2780CP70 and 16.7+/-6.8 % for A2780 at 72hrs and 25.6+/-6.3 % for A2780CP70
and 10.5+/-3.7 % for A2780 at day 14. These differences were significant with p <0.05
at 24hrs; p <0.05 at 72hrs and p <0.05 at day 14 (see fig 8.3).
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Figure 8.2 - The % of cells within each high-powered field where virus was










The size of tumours was monitored over the 14 day cycle following viral injection. No
difference in tumour size was found between the two cell lines. This was to be expected
given that a single dose of virus was administered of a relatively low dose.
These results indicate that the dll520 virus can replicate in both p53 null and competent
cell line xenografts in a murine model as in both cell types the level of virus rose
between 24 and 72 hrs. The level ofviral presence and replication is significantly higher
in p53 negative cell lines at all time points assessed. This difference is significant at all
time points and applies both in terms of viral density and viral distribution within the
xenografts. This supports the hypothesis that the dll520 virus can replicate preferentially
in p53 deficient cells in a tumour model. The difference is present at all time-points
assessed but is maximal at 72 hrs. This would suggest that the difference is due to a
differential level ofviral replication and not simply viral survival as there was an
increase in viral presence at 72 hrs compared to 24 hrs.
8.3 - Discussion
8.3.1 - Replication and Spread in a Matched p53 Tumour Model
Using p53 matched human tumour xenografts in a murine model demonstrated that the
dll520 virus replicates and spreads preferentially in p53 negative tumours. Viral
presence was assessed in two ways:
1. As a percentage of the interface between the necrotic tumour centre and the
surrounding cells where virus was detected.
2. As a percentage of cells where virus was localised in those areas where virus was
detected.
These results demonstrate that in both cell lines there is maximal virus detected at 72hrs,
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rising from the 24-hr time-point and then declining at the 14 day time-point. This is in
keeping with the expected pattern of virus replication within the tumour xenografts in
both cell lines which would be maximal at 72 hrs, and would be greater in p53 null cell
lines. In the A2780CP70 p53 null cell lines there was evidence ofmore widespread
detection of virus where hexon expression was counted as a percentage of fields where
virus was detected and that within these fields a higher percentage of virus was detected.
It is reasonable to presume a higher level of virus replication therefore in the A2780
CP70 cell line.
Previous work has demonstrated a higher level of tumour growth inhibition in p53 null
cell lines using the dll520 virus [1], This was presumed to be an effect of differential
viral replication but no measurement of virus within the xenografts was performed. We
demonstrated that there is a differential level of virus within the p53 matched tumour
cell line xenografts and that this is due to increased replication of the virus in the p53
mutant cell line.
These experiments demonstrate that the virus replicates preferentially in p53 deficient
cell lines in a xenograft model. In this experiment infectivity was not 100%. It is known
the dl 1520 is less infective than the wild type adenovirus, which may explain this
feature, which is in keeping with similar previous experiments [5]. It is clear that the
virus can also exist and replicate in tumour cells with a functional p53 but to a far lesser
extent. A small number of groups have reported results with the dl 1520 virus disputing
the p53 selectivity of cell killing. Rothmann et al conducted tissue culture experiments
with various human cell lines of both functional and dysfunctional p53 status [127].
They reported that replication of the virus was independent of p53 status in many cell
types. Our results, using a xenograft model, would indicate that if exactly matched cell
line is used the level of replication, and therefore any likely anti-tumour activity, is
related to p53 status of the tissue.
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CHAPTER 9 - EFFECT OF VARYING THE
CARRIER MEDIUM ON VIRAL DISTRIBUTION
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9 - Comparison of a single intra-tumoural injection of di1520 in a2780cp70
tumour xenografts using varying carrier media
9.1 - Materials and methods
Tumour xenografts ofA2780CP70 were raised as described earlier. Once tumours were
established they were injected with the investigational material. Four cohorts of 30
tumours each were injected with either:
1) 108 plaque forming units (pfu) dll 520 in lOOul PBS.
2) 108 pfu dll520 in lOOul 1% lignocaine.
3) 108 pfu dll520 in lOOul 200iu/ml hyaluronidase solution.
4) 108 pfu dll520 in lOOul 1% lignocaine containing 200iu/ml hyaluronidase.
Tumours were harvested at 4hrs, 24hrs, 72 hrs or at a period up to 14 days determined by the
maximal accepted size of the xenografts. They were then fixed in 4% phosphate buffered
formalin.
An experiment to determine if varying the carrier medium could enhance the distribution
of dll 520 adenovirus was devised. Xenografts of the A2780CP70 p53 deficient cell line
were assessed for the presence of adenoviral hexon following harvesting at different
time-points following a single injection of dll 520 in various carrier media. Distribution
was calculated as a % of high-powered fields for each histological section containing any
cells staining positive for adenoviral hexon protein. As in the previous experiment, the
necrotic centers of tumours were not included in this assessment, as it is known the virus
exists outwith this area.
An injection of the dll 520 adenovirus was made in to tumour xenografts as detailed in
materials and methods. The time-points used for assessment were with tumour harvest at
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4 hrs; 24 hrs; 72 hrs and 14 days following a single injection. The carrier media used
were standard PBS; 1% lignocaine; 200iu/ ml hyaluronidase and 1% lignocaine with
200iu/ ml hyaluronidase. Following tumour harvest the specimens were preserved in
formalin and processed for immunohistochemical staining with the hexon anti-body as
detailed previously. Distribution of virus was assessed by calculating the % of high-
powered fields with any cells staining positive for virus in each histological section (see
figures 9.1-9.4).
9.2 - Results
Values are shown along with the standard deviation for each value. Student's t-test was
applied to these results to determine their statistical significance (as shown by the p
values in parentheses).
At four hours following the injection ofdll 520 the % of fields with cells +ve positive
for hexon protein was:
1. 12.5+/-3.5 % with PBS as a carrier medium
2. 20.2+/-2.2 % with 1% lignocaine as a carrier medium (p<0.05)
3. 19.1+/-2.4 % with 200iu/ml of hyaluronidase as a carrier medium (p<0.05)
4. 31.9+/-5 % with 200iu/ml of hyaluronidase in 1% lignocaine as a carrier medium
(p<0.01)
There is a significant increase in distribution in groups 2-4 compared with group 1
(control) with the p values as shown above (see fig 5.1). This indicates that at the four-
hour time-point the effect of lignocaine and hyaluronidase is to increase the distribution
of the adenovirus within tumour xenografts following a single intra-tumoural injection.
At 24 hours following the injection of dll 520 the % of fields with cells +ve positive for
hexon protein was:
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1. 28.5+/-3.8 % with PBS as a carrier medium.
2. 62+1-6.2% with 1% lignocaine as a carrier medium (p<0.001).
3. 57+/-6.4% with 200iu/ml of hyaluronidase as a carrier medium (p<0.001).
4. 63.5+/-4.9 % with 200iu/ml of hyaluronidase in 1% lignocaine as a carrier medium
(pO.OOOl).
There was a significant increase in distribution in groups 2-4 compared with group 1
with the p values as shown above when Student's t-test was applied (see fig 5.2). This
indicates that at the twenty-four hour time-point the effect of lignocaine and
hyaluronidase is to increase the distribution of the adenovirus within tumour xenografts
following a single intra-tumoural injection.
At 72 hours following the injection of dl 1520 the % of fields with cells +ve positive for
hexon protein was:
1. 44.2+/-5.2 % with PBS as a carrier medium
2. 71.8+/-5.6 % with 1% lignocaine as a carrier medium (p<0.001)
3. 78.5+/-4.2 % with 200iu/ml of hyaluronidase as a carrier medium (pO.OOOl)
4. 64.6+/-9.4 % with 200iu/ml of hyaluronidase in 1% lignocaine as a carrier medium
(p<0.05)
There was a significant increase in distribution in groups 2-4 compared with group 1
with the p values as shown above when Student's t-test was applied (see fig 5.3). This
indicates that at the seventy-two hour time-point the effect of lignocaine and
hyaluronidase is to increase the distribution of the adenovirus within tumour xenografts
following a single intra-tumoural injection.
At 14 days following the injection of dl 1520 the % of fields with cells +ve positive for
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hexon protein was:
1. 28.7+/-9.1 % with PBS as a carrier medium
2. 50.9+/-6.4 % with 1% lignocaine as a carrier medium (p<0.05)
3. 56.1+/-5.7 % with 200iu/ml of hyaluronidase as a carrier medium (p<0.01)
4. 49.4+/-8.S % with 200iu/ml of hyaluronidase in 1% lignocaine as a carrier medium
(p<0.05)
There was a significant increase in distribution in groups 2-4 compared with group 1
with the p values as shown above when Student's t-test was applied (see fig 5.4). This
indicates that at the fourteen-day time-point the effect of lignocaine and hyaluronidase is
to increase the distribution of the adenovirus within tumour xenografts following a
single intra-tumoural injection.
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Figure 9.1 - typical viral distribution at 72hrs using PBS as a carrier
Fig 9.2 - typical viral distribution at 72hrs using lignocaine as a carrier
I66
Fig 9.3 - typical viral distribution at 72hrs using hyaluronidase as a carrier
Fig 9.4. - typical viral distribution at 72hrs using hyaluronidase and
lignocaine as a carrier
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Figure 9.5 - Distribution of dl1520 virus following a single intra-tumoural
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These results demonstrate a significant increase in the distribution of dl 1520 adenovirus
when either hyaluronidase or lignocaine is used as a carrier medium to deliver the virus.
Combining lignocainc and hyaluronidase as a carrier medium did not significantly
increase this advantage compared to using either agent singly. This difference was
apparent at all time points assessed indicating that the effect is due at least in part to an
immediate distribution effect. The different carrier media do not adversely affect the
survival of the virus as indicated by the fact that virus was detected up to 14 days post
injection.
This shows that a better distribution of the adenovirus dl 1520 throughout a tumour can
be achieved by varying the carrier medium. The agents used are in common clinical use
and as such are known to be non-toxic in the required dose range. It is possible that
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increasing the distribution of a virus in this way could increase its therapeutic effect.
9.3 - Discussion
Using a murine xenograft model it was demonstrated that by varying the carrier medium
used to deliver the dl 1520 adenovirus the distribution of the virus could be increased.
Both lignocaine and hyaluronidase has this effect when compared to using PBS as a
carrier medium. This effect is noted using each agent alone or in combination.
Hyaluronidase is an enzyme that depolymerises hyaluronic acid in the ground substance
of tissue interstitium. Hyaluronic acid is a mucopolysaccharide present in the ground
substance of tissues and forms highly viscous fluids. Once depolymerised it forms a
watery fluid, which facilitates distribution of substances within the ground substance of
tissues. It has long been known to increase the spread of local anaesthetic when utilised
as a subcutaneous or intra-dermal injection and can decrease the time taken for
distribution [175]. An increase in the area of distribution has also been noted previously
when hyaluronidase is combined with local anaesthetics [145]. One can speculate that
these effects might both be noted when injecting adenovirus intra-tumourally hence
explaining the increased viral distribution, although this mechanism of action has not
been confirmed.
Lignocaine is a commonly used local anaesthetic agent. It acts by blocking the voltage
dependent sodium channels in excitable tissues thereby preventing impulses travelling in
pain sensitive nerves [176], This blocking is not however confined to nervous tissue and
the smooth muscle of arterioles is also affected causing a relaxation of these cells with
resultant vasodilatation [177, 178]. Local vasodilatation of arterioles would increase the
blood flow around the tumour xenograft where the intra-tumoural injection was made,
potentially increasing the spread of a substance within the tumour. This increased blood
flow might explain the observed increase in viral distribution, although this cannot be
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confirmed.
As the hyaluronidase and lignocaine act by independent means to increase the
distribution of virus it is possible that they could have an additive effect although no
synergy was demonstrated in this series. Further studies might be able to explain this
lack of synergistic effect. These results have considerable significance for viral therapy
in general. It has been noted previously that dl 1520 tends to be seen preferentially
around the interface between the necrotic central areas of tumours and the peripheral
tumour cells [1, 137]. Any process whereby virus can be encouraged to spread within the
tumours could lead to an enhanced anti-tumour activity as a greater proportion of the
tumour could be affected at any one time. It has previously been demonstrated in a
xenograft model that increasing viral distribution by other means, namely using multiple
divided doses for administration and increasing the volume of viral suspension, could
lead to enhanced anti-tumour effect in p53 null cell lines [131, 132]. It would follow that
increasing distribution by altering the carrier medium could have the same effect. This
effect could benefit any gene therapy protocols where an adenovirus is used as a carrier
and a local injection is utilised.
There are safety issues concerned with any therapy that might increase dissemination of
tumour cells following an intra-tumoural injection. As lignocaine is frequently used in
all surgical fields with no adverse effects it is reasonable to assume that the local
vasodilatation it causes does not lead to such dissemination. The safety of intra-tumoural
injection of hyaluronidase would have to be further investigated prior to any clinical
trials being undertaken. In theory it is possible that the action of hyaluronidase in
disrupting the ground substance of tissues could lead to a risk of embolisation and
possible metastasis of tumour deposits. Further work using an animal model to look at
this aspect of treatment would be required before any trials in humans would be
suggested.
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9.4 Summary of results
The above laboratory work has shown the following points in a tissue culture and murine
xenograft model.
1. The virus can act in an additive fashion with standard chemotherapeutic agents to kill
cancer cells. Cells of both mutant and wild type p53 status can be killed but the effect is
very much greater in p53 null cells if sufficient time for viral replication is allowed.
2. Following a direct intra-tumoural injection spread and replication of the virus is
influenced by the p53 status of the cell line used. Both spread and replication of virus are
greatest in p53 null cell line tumours.
3. Varying the carrier medium can influence the spread of the virus with no detrimental
influence on viral replication. Two commonly used agents, lignocaine and
hyaluronidase, were used to successfully increase the spread of the virus following a
single intra-tumoural injection.
We have therefore shown several points that would support the use of dl 1520 as a
selective anti-cancer agent. These results support the concept that this selectivity is based
on the p53 status of tumour cells.
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CHAPTER 10 - CONCLUSIONS AND
SUGGESTIONS FOR FURTHER RESEARCH
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10 - Conclusions
This thesis is concerned with both laboratory based and clinical studies concerned with
the selectivity, delivery and mechanism of action of the novel anti-cancer agent dl 1520.
This adenovirus represents part of an exiting new field of potential treatments for cancer,
that of gene therapy. The virus acts by exploiting a fundamental genetic defect that is
present in most human solid malignancies, mutation of the p53 tumour suppressor gene.
The above results of the series of laboratory experiments demonstrated success in adding
to our knowledge of the mechanism of action and p53 selectivity of the virus; of how to
optimise virus delivery and whether the agent can be used in combination with
chemotherapy. The results of a clinical trial involving the dl 1520 attenuated adenovirus
have added to our knowledge about the likely mechanism of action of the agent and
about its safety in clinical use.
The aims of the thesis were set out as follows:
Laboratory experiments were performed to further clarify:
1. The mechanism of action of dll520
2. The p53 specificity of the virus both in vitro and in vivo
3. Optimisation of intra-tumoural virus delivery
4. The effect of combining the virus with other standard chemotherapeutic agents
The clinical trial was devised to evaluate in a human model:
1. The mechanism of action of dll520
2. The p53 specificity of the virus in vivo
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Optimisation of intra-tumoural viral delivery
Tolerance of administration of dll520 in a select patient group
Immune cell response to the virus
Level of tumour necrosis following viral administration
10.1 - Laboratory based experiments
10.1.1 - The mechanism of action of dl1520
Significant information as to the mechanism of action of the agent was gleaned from a
clonogenic analysis of the effect of using the virus in conjunction with chemotherapeutic
agents (cisplatin and 5-fluouracil). It was found that the virus had a significantly
enhanced level of cell kill when used against a p53 null cell line as opposed to the p53
functional equivalent line (A2780CP70 compared to A2780). This difference only
manifests after the virus is left for a 72 hr incubation with the cells as opposed to a 24 hr
incubation, where levels of cell kill are roughly comparable between the cell lines. We
propose that this time dependent difference shows that the mechanism of cell killing
following inoculation with the virus is cytolysis following viral replication. It requires a
72hr inoculation with the virus to allow time for viral replication to become maximal to
show the increased cell kill in the p53 null cell line which is permissive for replication of
the dl 1520 virus. After 24 hrs there is no difference between the two, as viral replication
has not progressed sufficiently to demonstrate a replication dependent difference. This
experiment therefore supports the hypothesis that the dll520 virus kills cells mainly by
cytolysis, and this is the mechanism which allows selectivity between tissue ofwild-type
or mutant p53.
10.1.2 - The p53 specificity of the virus both in-vitro and in-vivo
The same experiment also gives information to support the theory of p53 selectivity of
the virus. As detailed above a significant increase in cell kill following inoculation with
the virus was demonstrated in p53 null cell line as compared to the similar cell line with
a functional p53. This difference was time dependent and only manifest after a 72 hr
time period, as would be predicted where the differential effect was dependent on viral
replication. This replication in an adenovirus is maximal after 72 hrs.
A tumour xenograft model was also used to investigate any differences in viral
replication in tumours grown from cell lines similar except for p53 status. A single
injection of the virus was made into tumours of differing cell type and the tumours
harvested at different time points following the injection. It was shown that both viral
distribution and quantity was significantly higher in p53 mutant xenografts as compared
to tumours grown from p53 competent tissues. This experiment successfully
demonstrates p53 selectivity of dl 1520 in a tumour xenograft in-vivo model.
10.1.3 - Optimisation of intra-tumoural virus delivery
Using a tumour xenograft model it was successfully demonstrated that delivery of the
virus could be increased by varying the carrier medium used for injection. Two agents
were tested:
1. T.ignocaine - a commonly used local anaesthetic agent which can also act as a vaso¬
dilator.
2. Hyaluronidase - an enzyme, which acts to liquefy tissue interstitium, leading to
increased distribution of injected agents.
Both of these agents caused an increased distribution of the virus when used as a carrier
medium. The activity of the virus might be increased with optimisation of its distribution
and it is possible that this could lead to increased activity of the virus.
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Several further experiments to clarify this could be undertaken. The same xenograft
model could be used with a higher dose of virus or with multiple doses to deliver
sufficient virus to cause tumour shrinkage. Tumours grown on the same mice could have
either standard PBS as a carrier or either hyaluronidase or lignocaine. A comparison of
effect on tumour growth could then be made. It would also be useful to investigate
whether the use of these agents in direct intra-tumoural injection leads to an increased
risk ofmetastases and a murine xenograft model could be used to investigate this.
If these studies were promising a clinical trial could be considered using either agent to
administer the virus. It would however have to be clear that neither agent was likely to
cause seeding of tumour cells to distant sites.
10.1.4 - The effect of combining the virus with other agents
A model of anti-tumour activity of the virus using clonogenic analysis was devised to
allow investigation of the effect of combining the virus with either cisplatin or 5-
fluorouracil. In this model it was successfully shown that the virus can act in an additive
fashion with chemotherapeutic agents. This effect is seen at both 24hrs and 72 hrs
incubation with the virus and with both p53 wild-type and mutant cell lines. From this
we can deduce that the virus could be used alongside such agents in the treatment of
cancer, particularly in those cases where chemotherapy alone might have been used.
There was no evidence of antagonistic action between the virus and other agents.
The same model could be used in the future to investigate the effect of using the virus
with other chemotherapeutic agents. It would also be possible to test the agent in
combination with chemotherapy in an in-vivo model, using a murine xenograft model.
The virus could be delivered into tumours by direct intra-tumoural injection along with
systemic administration ofwhichever chemotherapy agent is under investigation. Such
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studies have already been successfully undertaken using both cisplatin and 5-fluorouracil
and this model could be similarly used to test other agents [1].
10.2 - Clinical trial of a single injection of d!1520
10.2.1 - The mechanism of action of d!1520
It had been hoped that the clinical trial of a single intra-tumoural injection of dll520
would add to our knowledge of the mechanism of action of the virus in-vivo following
direct intra-tumoural administration. It was found however that following a single
injection we could not grossly demonstrate significant tumour necrosis. As mentioned in
the discussion section this was probably due to the relatively small amount of virus being
used. A small amount of cytolysis was however noted around the areas where adenovirus
was detected. This supports the theory that the virus can kill cancer cells by cytolysis.
This effect was only noted in specimens harbouring a mutant p53 genotype. By contrast,
in normal tissues injected with the virus a relatively high level of apoptosis was noted,
significant at th 24 hr time-point. This seems to demonstrate that normal tissues respond
to the virus by allowing apoptotic cell death, which would be expected to be an early
event. These findings give further evidence that the virus can kill p53 mutant cancer
cells by cytolysis but in normal, p53 wild-type tissues cause apoptosis as an early event.
This is in keeping with the purported mechanism of selectivity of the agent, which
should in theory give this effect in p53 competent cells. This effect was not seen in p53
wild-type tumour cells perhaps indicating a defect elsewhere in the p53 mediated
apoptosis pathway.
10.2.2 - The p53 specificity of the virus in-vivo
The above clinical trial demonstrated convincingly that the virus exists preferentially in
tumour tissue rather than normal tissue. The only two samples of normal tissue where
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the virus was detected had abnormalities of p53 on immunohistochemical staining. It
could be assumed that this difference between normal and tumour tissue was due to the
likely differing p53 status of the tissues. Gene sequencing was not however performed
on the normal tissue biopsies and so it is only possible to make deductions from the
immunohistochemistry results. We were not able to demonstrate a statistically
significant difference in viral presence or replication between tumour samples of
differing p53 status. More virus was found in p53 mutant tumours, but as only 3 tumours
had a wild-tpe p53 sequence, a statistical significance could not be demonstrated.
The most we can confidently say from this trial is that the virus preferentially survives
and replicated in tumour tissue as opposed to normal tissue following direct injection.
This is likely to be related to p53 status, but we were unable to demonstrate this in a
statistically significant manner. Further studies to pursue this might include similar
studies of a larger size where more tumours ofwild-type p53 status are investigated.
Analysing normal tissue samples by gene sequencing might also be of benefit if a similar
trial were to be conducted in the future. We could then say with certainty whether these
normal tissue samples did have a normal p53 or if the gene for this protein had been
damaged as part of a field change. Our study demonstrated that the dll 520 virus can
exist in normal tissue, in this case in two samples out of fifteen, but it is not clear if these
samples all had a fully functional p53 protein. Both the samples where virus was found
did demonstrate positive immunohistochemical staining for p53, possibly indicating
abnormal protein.
10.2.3 - Optimisation of intra-tumoural viral delivery
The clinical trial showed that direct intra-tumoural delivery of the virus is possible and
safe. The patients tolerated injections and no significant side effects were noted. It has
been previously noted that multiple rather than single injections lead to optimisation of
delivery and spread of the virus. An in-vivo animal model has also shown that
178
maximising the volume of diluent used to administer the virus can lead to increased viral
spread [132]. It is therefore likely that if the trial was repeated using multiple injections
rather than a single injection, wider distribution of the virus would have been found.
Other trials have demonstrated that higher doses of this virus can be safely used in
similar groups of patients and so multiple injections of the same dose (1010 pfu) could be
used.
10.2.4 - Tolerance of administration of dl1520
Patients with primary intra-oral squamous carcinoma tolerated the viral injections well.
Some pain and swelling at the injection site was noticed but there were no dose limiting
toxicity. Most significantly, the study clearly demonstrates that the virus does not harm
normal, non-tumour tissue. A significant injection of the virus was given to an area of
normal tissue within the mouth of each subject. This did not result in any case of gross
damage to this area and we have shown very little virus surviving in these tissues. The
virus is therefore well tolerated and safe in this patient group.
10.2.5 - Immune system response to the virus
Our results did indicate that a single injection of the virus did lead to a transient drop in
CD4+ lymphocytes following an injection. This effect was noted at the 24hr timepoint
and seemed to disappear by 72 hrs. The cause of this is not clear at present, but did not
seem to have a deleterious effect on the subjects in the trial. This phenomenon has not
previously been noted.
10.2.6 - Suggestions for further work
Dll 520 remains a promising agent for the treatment of SCC of the head and neck. It
appears to be safe and well tolerated and in the clinical setting to be specific for tumour
tissue as compare to normal tissue. This selective effect is probably due to the action of
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the p53 gene in causing apoptosis in normal tissues although the mechanism of action of
the virus in p53 wild-type tumour tissues requires further investigation.
Clearly there are many possible avenues for further research using this agent. The virus
has already been tested in phase II trials where patients with recurrent SCC of the head
and neck were treated with direct intra-tumoural injections of the virus alone or in
combination with intra-venous chemotherapy [138, 139]. A logical extension of this is a
phase III trial where patients are randomised to receive chemotherapy alone or
chemotherapy plus the dll520 adenovirus. Such a trial is at present underway and once
completed should allow conclusions as to the efficacy of this agent in such cases, as
compared to standard treatment regimes.
All of the work contained in this thesis has been concerned with direct administration of
the virus. One of the key concepts with this attenuated adenovirus is however its
purported selectivity of action. This selectivity should in theory allow the virus to be
delivered systemically rather than locally. Systemic delivery would allow the treatment
of clinically invisible tumour deposits and deposits not accessible to direct injection.
A clinical trial looking at regional delivery of the virus to patients with metastatic liver
tumours (emanating from primary colo-rectal cancer) found that the virus could be safely
administered via the hepatic artery at a dose of 3X1011 pfu [140]. The same group also
found that intra-venous administration up to the same dose was safe. A clinical trial with
patients suffering metastatic deposits of tumour in the lung has also demonstrated the
safety and feasibility of intra-venous delivery of the virus [142]. Doses of up to 2X1013
pfu of adenovirus were used with no dose limiting toxicities.
In the case of SCC of the head and neck, direct intra-tumoural injection of the virus is
relatively straightforward as the recurrent tumour deposits usually affect the cervical
neck nodes and are therefore amenable to direct injection. The above trials do however
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suggest that intravenous delivery would be possible in such cases, and would have the
advantage ofallowing treatment ofclinically non-apparent micro-metastases and allow
any distant metastatic lesions present to also receive treatment. In the future a trial of
systemic administration ofdll520 to patients suffering with recurrent SCC of the head
and neck could be envisaged.
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Appendix 1 - Abbreviations
Cdk - cyclin dependent kinase
ISH - in-situ hybridisation
MOI -multiplicity of infection
Mut -mutant
PBS - phosphate buffered solution
PFU - plaque forming units
SCC - squamous cell carcinoma






PE -ve Becton Dickinson.









ABC reagent - Vectastain ABC kit.
DAB - Vector Laboratories
Hexon - mouse anti-adenovirus monoclonal antibody Iglk isotype (Chemicon).
Hexon detection - Biogenex Super Sensitive Immunodetection System, Biogenex.
Blocking serum - Horse IgG, Vectastain ABC kit.
Secondary anti-body - biotinylated antibody, Vectastain ABC kit.
Tunel reagent and Converter POD - Boerringer Manheim in-situ cell death detection kit.
Very Intense Purple - Vector Laboratories.
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In-situ hybridisation
Anti-biotin/ alkaline phosphatase conjugate - Vector laboratories
Biotinylated adenoviral DNA probe - ENZO diagnostics
NBT/BCIP - Vector laboratories
Post-hybridisation reagent - ENZO diagnostics
Tween 20 - Vector laboratories
Block
Power Block casein solution, Biogenex.
Buffers
Colour development buffer - lOOmM Tris, pH 9.5; lOOmM NaCl; 50mM MgC12.
Proteinase K buffer - 50mM Tris, pH 7.5; 5mM EDTA.
Sodium tricitrate buffer (2.94 g sodium tricitrate in 11 distilled water adjusted to pH 6
with HCL).
Enzymes
Protease - Pronase, Meridian diagnostics
Protienase K - Biogenix
Fixatives




0.1% Triton X-100 - Sigma
Stains and histology reagents.
Mayer's hematoxylin - Vector laboratories
Methyl green - Vector Laboratories.
Nuclear fast red - Vector laboratories.
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